Top

Jennifer Wargo, M.D., M.M.Sc.

Department of Surgical Oncology, Division of Surgery

About Dr. Jennifer Wargo

Jen Wargo’s career commitment has always been to advance the understanding and treatment of disease through science. After completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital where she became interested in the biology and treatment of cancer. During her training, she completed two fellowships in surgical oncology with a focus on cancer immunotherapy.

She was recruited to MGH in 2008 to join the faculty in the Division of Surgical Oncology and established a translational research laboratory focusing on better understanding response and resistance to treatment for melanoma, pancreatic cancer, and other cancers. During that time, her laboratory demonstrated that treatment with molecularly targeted therapy could sensitize tumor cells to treatment with immunotherapy, providing the rationale for combined targeted therapy and immunotherapy combinations. She also began studies on the tumor microbiome in pancreatic and other cancers while at Harvard.

Jen was recruited to the University of Texas MD Anderson Cancer Center in 2013 to help lead the Melanoma Moonshot efforts - and also continued important translational research work on targeted therapy, immunotherapy, and the impact of the gut and tumor microbiome in cancer. Jen is currently a Professor of Surgical Oncology and Genomic Medicine, and the leader of the Platform for Innovative Microbiome and Translational Research (PRIME-TR) at MD Anderson. Importantly, Jen is deeply invested in working with investigators across the institution and across the world to find better ways to treat, intercept, and ultimately prevent cancer.

Primary Appointment

Endowed Professor R. Lee Clark Endowed Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Inaugural Member, Department of James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX

R. Lee Clark Endowed Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2012	Harvard University, Cambridge, Massachusetts, US, MMSc in Medical Science
1998	Medical College of Pennsylvania, Philadelphia, Pennsylvania, US, MD
1994	Gwynedd-Mercy College, Gwynedd Valley, Pennsylvania, US, BS in Biology
1990	Gwynedd-Mercy College, Gwynedd Valley, Pennsylvania, US, AS in Nursing

Postgraduate Training

2006-2008	Clinical Fellowship, Surgical Oncology, National Institutes of Health, National Cancer Institute, Bethesda, Maryland
2003-2005	Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, Massachusetts
2001-2003	Research Fellowship, Surgical Oncology, University of California Los Angeles, Los Angeles, California
1999-2001	Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, Massachusetts
1999-2001	Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, Massachusetts

Licenses & Certifications

2014	Medical License
2006	American Board of Surgery

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2019

Associate Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2019

Assistant Professor, Department of Genomic Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, 2013 - 2015

Assistant Professor, Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 2013 - 2015

Assistant Professor, Department of Division of Surgical Oncology, Massachusetts General Hospital and Harvard University, Boston, MA, 2013 - 2013

Instructor, Department of Surgical Oncology, Massachusetts General Hospital and Harvard University, Boston, MA, 2008 - 2013

Instructor, Department of General Surgery, Massachusetts General Hospital and Harvard University, Boston, MA, 2005 - 2006

Administrative Appointments/Responsibilities

Member, The University of Texas MD Anderson Cancer Center, Tissue Oversight Committee, Houston, TX, 2019 - Present

Member, The University of Texas MD Anderson Cancer Center, Odyssey Program Advisory Committee, Houston, TX, 2019 - Present

Program Director, Platform for Innovative Microbiome and Translational Research (PRIME-TR), Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Principal Investigator, T32 Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present

Leader, Melanoma Moon Shot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present

Member, Breast Cancer Moonshot SAB Committee, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

Member, Immunotherapy Platform Executive Committee, Department of Surgical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Co-Lead, Melanoma Moon Shot - Tissue Acquisition Team, Department of Surgical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Leader, Biospecimen Collection Team, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Leader, APOLLO Effort for Melanoma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Other Professional Positions

Consultant, Daiichi Sankyo/UCB Japan, 2023 - Present

Consultant, Gustave Roussy Cancer Center, 2023 - Present

Consultant, PeerView, New York, NY, 2023 - Present

Consultant, Bayer Therapeutics, Whippany, NJ, 2023 - Present

Consultant, OSE Immunotherapeutics, 2023 - Present

Consultant, Micronoma, San Diego, CA, 2021 - Present

Consultant, Biothera Pharmaceuticals, Eagan, MN, 2020 - 2023

Consultant, Merck, Kenilworth, NJ, 2020 - 2022

Member, AAI Membership Committee, San Diego, CA, 2019 - Present

Co-Chair, AACR Annual Meeting Program Committee, Philadelphia, PA, 2019 - Present

Consultant, AstraZeneca, Boston, MA, 2017 - 2022

Regular Member, The University of Texas Health Science Center, The Graduate School of Biomedical Sciences, Houston, TX, 2016 - Present

Consultant, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2015 - 2023

Consultant, Bristol-Myers Squibb, Princeton, NJ, 2013 - 2022

Consultant, Roche/Genentech, Houston, TX, 2013 - 2022

Consultant, GlaxoSmithKline, Houston, TX, 2013 - 2022

Supervising Physician for Mid-Level Providers, Massachusetts General Hospital, Boston, MA, 2010 - 2013

Member, MGPO Nominating Committee, Massachusetts General Hospital, Boston, MA, 2010 - 2013

Member, Massachusetts General Hospital, Boston, MA, 2005 - 2006

Assistant Surgeon, Massachusetts General Hospital, Boston, MA, 2004 - 2013

Extramural Institutional Committee Activities

Member, Dept. of Immunology, Physician-Scientist Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, QIAC Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Institute for Personalized Cancer - Targeted Clinical Investigation Group, The University of Texas MD Anderson Cancer Center, 2014 - Present

Editorial Activities

Editor, Cell, 2020 - Present

Honors & Awards

2025 - Present	2025 Jonathan Kraft Prize for Excellence in Cancer Research, Mass General Krantz Family Center for Cancer Research
2023	Edith and Peter O’Donnell Award, Texas Academy of Medicine, Engineering, Science & Technology
2023	Sergio Lombroso Award in Cancer research, Weizmann Institute of Science
2021	Estrela Medrano Memorial Award, Society for Melanoma Research
2021	The Mark Foundation Endeavor Award, The Mark Foundation for Cancer Research
2020 - 2021	Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, The University of Texas MD Anderson Cancer Center
2020 - 2021	Texas Business Women's Award, Texas Business & Professional Women’s Foundation
2019	R. Lee Clark Prize, MD Anderson Cancer Center
2018	Outstanding Investigator Award, Society for Melanoma Research
2017 - 2019	Andrew Sabin Family Foundation Fellowship, MD Anderson Cancer Center
2017	Stand Up 2 Cancer Award - Innovative Research Grant, AACR
2016	Finalist for Chamberlain Distinguished Mentor Award
2015 - 2016	Knowledge Gap Seed Funding, University of Texas System
2014 - 2017	Rising STARS Award, The University of Texas System
2014 - 2016	The Regents' Health Research Scholars Award, The University of Texas System
2014 - 2015	Neufeld Memorial Research Grant Award, United States - Israel Binational Science Foundation
2014	Outstanding Young Investigator Award, Society for Melanoma Research
2011	Cancer Center 100 Award, Massachusetts General Hospital
2010	Patient's Choice Award, Patient's Choice
2010	Claflin Distinguished Scholar Award, Harvard University, Center for Faculty Development
2009	Gynecologic Oncology Teaching Award, Massachusetts General Hospital
2004	Excellence in Teaching, Tufts Medical School
2003	Harvey Baker Traveling Fellowship, Society of Surgical Oncology
1998 - 2024	Alpha Omega National Medical Honor Society
1998	Award for Excellence, Medical College of Pennsylvania
1998	Dean's Award, Medical College of Pennsylvania
1998	Donald R. Cooper Award, Medical College of Pennsylvania
1998	Janet Glasgow Memorial Achievement Citation, American Medical Women's Association
1998	Paula Bernocchi Award, Medical College of Pennsylvania
1998	Student Government Association Award, Medical College of Pennsylvania
1998	Student Research Award, Association for Academic Surgery
1997	Student Research Award, NIH/American Medical Student Association
1994	Departmental Honors (Biology), Gwynedd-Mercy College
1990	Recipient of St. Catherine's Medal, Kappa Gamma Pi, National Catholic Honor Society

Professional Memberships

National Academy of Medicine

2023 - Present

OSE Immunotherapeutics International Scientific Advisory Board

2022 - Present

Society for Immunotherapy Cancer

2022 - 2024

American Society for Clinical Investigation

2020 - Present

American Society for Clinical Investigation

2019 - Present

The Lancet Oncology International Advisory Board

2018 - Present

Harris County Medical Society

2014 - Present

South West Oncology Group

2014 - Present

The Society for Melanoma Research

2014 - Present

Society for Immunotherapy Cancer

2014 - Present

Society of Surgical Oncology

2007 - Present

American Society for Clinical Oncology

2007 - Present

American Association for Cancer Research

2007 - Present

American College of Surgeons

2006 - Present

Massachusetts Medical Society

1998 - Present

Alpha Omega Alpha National Medical Honor Society

1998 - Present

National Pathology Honor Society

1997 - Present

Pennsylvania Medical Society

1994 - Present

American Medical Association

1994 - Present

Selected Presentations & Talks

Local Presentations

2024. Targeting the microbiome to promote health and end cancer. Invited. Division of Cancer Medicine Grand Rounds. Houston, Texas, US.
2024. Understanding the role of the microbiome/diet in efficacy of immunotherapy. Invited. BTC Ovarian MRD Team Lab Meeting. Houston, Texas, US.
2024. The many face(t)s of gastrointestinal stromal tumor. Invited. Grand Rounds. Houston, Texas, US.
2023. Breaking the mold: chartering a new path to impact cancer care through science. Invited. K12 Scholars Symposium. Houston, Texas, US.
2023. Special Sessions. Invited. MD Anderson Cancer Center Board of Visitors Special Session. Houston, Texas, US.
2023. Forward Texas Accelerating Change. Invited. TAMEST 2023 Annual Conference. Houston, Texas, US.
2023. Targeting the microbiome and other factors to promote health and end cancer. Invited. 4th Annual Innovative Drug Discovery and Development Conference. Houston, Texas, US.
2023. Personal experience with the development of a robust research program focused on microbiome and immunotherapy. Invited. T32 Research Seminar Series. Houston, Texas, US.
2023. Targeting the tumor microenvironment and the microbiome to promote health and end cancer. Invited. Thoracic Retreat. Houston, Texas, US.
2022. Understanding responses to cancer therapy through translational research: the tissue is the issue, the scoop is in the poop, you are what you eat, and sex matters. Conference. Understanding responses to cancer therapy through translational research: the tissue is the issue, the scoop is in the poop, you are what you eat, and sex matters. Houston, TX, US.
2021. Abstract Participation for IOYIF. Conference. Abstract Participation for IOYIF. Houston, TX, US.
2018. Personalizing Therapy for Melanoma. Conference. Personalizing Therapy for Melanoma. Houston, TX, US.
2016. Immune Checkpoint Therapies. Conference. Immune Checkpoint Therapies. Houston, TX, US.
2015. Understanding the Dynamics and Heterogeneity of responses to melanoma therapy. Conference. Understanding the Dynamics and Heterogeneity of responses to melanoma therapy. Houston, TX, US.
2015. Understanding Response and Resistance to Melanoma Therapy. Conference. Understanding Response and Resistance to Melanoma Therapy. Houston, TX, US.
2015. Research Biopsies and Translation Research Protocol Participation. Conference. Research Biopsies and Translation Research Protocol Participation. Houston, TX, US.
2014. Update on the Melanoma Moonshot and APOLLO: Opportunities for collaborations with Head and Neck Oncology and Surgery at MDACC. Conference. Update on the Melanoma Moonshot and APOLLO: Opportunities for collaborations with Head and Neck Oncology and Surgery at MDACC. Houston, TX, US.
2014. Overview of Research Opportunities in Genomic Medicine: Wargo Lab. Conference. Overview of Research Opportunities in Genomic Medicine: Wargo Lab. Houston, TX, US.
2014. Unlocking the Mystery Response and Resistance to Targeted Therapy and Immunotherapy in Melanoma (and Other Cancers). Conference. Unlocking the Mystery Response and Resistance to Targeted Therapy and Immunotherapy in Melanoma (and Other Cancers). Houston, TX, US.

Regional Presentations

2024. Targeting the Microbiome to promote health and end cancer. Invited. UTIMCO town hall. Austin, TX, US.
2023. Presenting Your Data in Talks and Manuscripts. Invited. Cancer Immunotherapy Winter School (CIWS) 2023 program. Austin, Texas, US.
2021. The role of the gut and tumor microbiome in cancer. Conference. The role of the gut and tumor microbiome in cancer, US.
2021. New Strategies for stratification and longitudinal monitoring of microbiota. Conference. New Strategies for stratification and longitudinal monitoring of microbiota. Virtual, US.
2021. Microbiome Webinar. Conference. Microbiome Webinar. Virtual, US.
2020. Factors impacting the tumor microenvironment: lessons learned from melanoma. Conference. Factors impacting the tumor microenvironment: lessons learned from melanoma. Virtual, US.
2020. The Role of the Microbiome in Cancer Therapy. Conference. The Role of the Microbiome in Cancer Therapy. WEBINAR, US.
2018. Key Opportunities and Challenges for the Future of Cancer Treatment. Conference. Key Opportunities and Challenges for the Future of Cancer Treatment. San Francisco, CA, US.
2014. How Often Should Scanning Surveillance be Performed in patients with high-risk melanoma? - Intense Screening. Conference. How Often Should Scanning Surveillance be Performed in patients with high-risk melanoma? - Intense Screening. Phoenix, AZ, US.
2014. Are BRAF Inhibitors Immunotherapy? Yes. Conference. Are BRAF Inhibitors Immunotherapy? Yes. Boston, MA, US.
2014. Are BRAF Inhibitors Immunotherapy? - Yes. Conference. Are BRAF Inhibitors Immunotherapy? - Yes. Phoenix, AZ, US.
2014. Immunologic Effects of TK1 Therapy in Cancer: Role for Immune Checkpoint Combinations. Conference. Immunologic Effects of TK1 Therapy in Cancer: Role for Immune Checkpoint Combinations. Palm Beach, FL, US.
2014. Insights into Cancer Therapy: Better Living through Biopsies. Conference. Insights into Cancer Therapy: Better Living through Biopsies. Montgomery, TX, US.
2013. Understanding the Effects of Oncogenic BRAF on Tumor Immunity and the Microenvironment: Implications for Design and Analysis of Future Clinical Trials. Conference. Understanding the Effects of Oncogenic BRAF on Tumor Immunity and the Microenvironment: Implications for Design and Analysis of Future Clinical Trials, US.
2013. Understanding Response and Resistance to Therapy through Serial Biopsies. Conference. Understanding Response and Resistance to Therapy through Serial Biopsies, US.
2013. Understanding the Role of Tumor Stroma in Response and Resistance to BRAF-Targeted Therapy. Conference. Understanding the Role of Tumor Stroma in Response and Resistance to BRAF-Targeted Therapy, US.
2011. Primary Melanoma Management, Laparoscopic Distal Pancreatectomy Lecture. Conference. Primary Melanoma Management, Laparoscopic Distal Pancreatectomy Lecture, US.
2011. Effects of BRAF Inhibitors in Melanoma. Conference. Effects of BRAF Inhibitors in Melanoma, US.
2009. The Use of Adoptive Cell Transfer in the Treatment of Advanced Melanoma: Updates and New Directions. Conference. The Use of Adoptive Cell Transfer in the Treatment of Advanced Melanoma: Updates and New Directions, US.
2009. Adoptive Immunotherapy for Melanoma: Updates and New Directions Lecture. Conference. Adoptive Immunotherapy for Melanoma: Updates and New Directions Lecture, US.
2009. Adoptive Immunotherapy for Melanoma: Updates and New Directions. Conference. Adoptive Immunotherapy for Melanoma: Updates and New Directions, US.

National Presentations

2025. Targeting the Microbiome to promote health and end cancer. Invited. Kraft Prize Symposium. Boston, Massachusetts, US.
2024. Targeting the Microbiome to promote health and end cancer. Invited. Division of Cancer Medicine Grand Rounds. Houston, Texas, US.
2024. Breakout Session: The Microbiome and Immunotherapy. Invited. Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Winter School (CIWS). Austin, Texas, US.
2024. Next review of the SU2C Convergence. Invited. Scientific Summit. Coronado, CA, US.
2023. The tumor landscape: translating mechanism to therapy. Invited. 3rd NATURE – MSKCC conference. New York, US.
2023. Monitoring and Modulating the Microbiome to Promote Health and End Cancer. Invited. 38th Annual Tumor Microenvironment Course, US.
2023. Breaking the mold: chartering a new roadmap to impact care through science. Invited. Boston, MA, US.
2023. Cancer and The Microbiome. Conference. Interest Group on Cancer, Stem Cells, and Transplantation at the NAM Annual Meeting. Washington, DC, US.
2023. Next Generation Cancer Immunotherapy. Invited. The Interest Group on Cancer, Stem Cells, and Transplantation/ NAM Annual Meeting. Washington, DC, US.
2023. Targeting the Microbiome to promote Health and end Cancer. Invited. Laboratory of Cancer Biology and Genetics (LCBG) Lecture Seminar Series, US.
2023. Leadership Skill. Invited. SITC - WIN Leadership Institute 2023, US.
2023. Mechanism of Drug Resistance with Tumor Immunotherapy. Invited. SITC Strategic Planning Retreat, Utah, US.
2023. Making Cancer History. Invited. Dr. Peter Pisters at MD Anderson’s 24th annual Making Cancer History® seminar. Aspen, CO, US.
2023. Mentoring the next generation of cancer immunologists. Invited. Arthur and Sandra Irving Cancer Immunology Symposium. Boston, MA, US.
2023. Targeting the tissue microenvironment and microbiome to promote health and end cancer. Invited. 2023 Breakthroughs in Cancer seminar series. Stanford, CA, US.
2023. Targeting the microbiome and other factors to promote health and end cancer. Invited. SITC Engineering & Immuno-Oncology Workshop-Opening Keynote Lecture. Boston, MA, US.
2023. Precision Combination Therapy. Invited. AACR Annual Meeting, US.
2023. A holistic approach to promoting health and ending cancer. Invited. Laura and Isaac Perlmutter Cancer Center Research Seminar Series. New York, US.
2023. Targeting the tumor microenvironment and the microbiome to promote health and end cancer. Invited. RUMP Seminar Series, US.
2023. Harnessing the Power of Immunotherapy in Resectable Melanoma: Practical Guidance for Delivering Effective Care Through Adjuvant and Neoadjuvant Strategies. Invited. Melanoma Symposium SSO. Boston, MA, US.
2023. Immunity in Immunotherapy Responses: From Discoveries to Precision Oncology. Invited. 2023 SITC Spring Scientific. Denver, CO, US.
2022. Modulating the microbiome to promote health and end cancer. Conference. Modulating the microbiome to promote health and end cancer. New York, NY, US.
2022. Targeting the Gut and Tumor Microbiome in Cancer. Conference. Targeting the Gut and Tumor Microbiome in Cancer. Virtual, US.
2022. Stories I: Scientific Trajectories. Conference. Stories I: Scientific Trajectories. Boston, MA, US.
2022. Targeting the microbiome to promote health and end cancer. Conference. Targeting the microbiome to promote health and end cancer. Virtual, US.
2022. Understanding Responses to Cancer Therapy: The Tissue Is the Issue, The Scoop Is in the Poop, and You Are What You Eat. Conference. Understanding Responses to Cancer Therapy: The Tissue Is the Issue, The Scoop Is in the Poop, and You Are What You Eat. New York, NY, US.
2022. Future Directions for Research and New Management Approaches in Immunotherapy Toxicities. Conference. Future Directions for Research and New Management Approaches in Immunotherapy Toxicities. Houston, TX, US.
2022. Targeting the Tissue and Tumor Microenvironment and Microbiome to Promote Health and End Cancer. Conference. Targeting the Tissue and Tumor Microenvironment and Microbiome to Promote Health and End Cancer. San Diego, CA, US.
2022. Targeting microbes to promote health and end cancer. Conference. Targeting microbes to promote health and end cancer. New Orleans, LA, US.
2021. Molecular Biology in Clinical Oncology Workshop: Grant Training and Lecture. Conference. AACR. Virtual, US.
2021. CANCER, MICROBIOME AND VIROME: The Role of the Tumor and Gut Microbiome in Cancer. Conference. CANCER, MICROBIOME AND VIROME: The Role of the Tumor and Gut Microbiome in Cancer. Virtual, US.
2021. Microbes, Viruses and Cancer Symposium: The role of the gut and tumor microbiome in cancer. Conference. Microbes, Viruses and Cancer Symposium: The role of the gut and tumor microbiome in cancer. Virtual, US.
2021. The role of the microbiome in response and toxicity to therapy. Conference. Sony Biotechnology. Virtual, US.
2021. The Impact of Gut and Tumor Microbiota on Response and Toxicity to Cancer Therapy. Conference. The Impact of Gut and Tumor Microbiota on Response and Toxicity to Cancer Therapy. Virtual, US.
2021. Microbiome transplantations versus diet. Conference. Microbiome transplantations versus diet. Virtual, US.
2021. The microbiome and cancer: Minimizing the hype and illuminating the hope. Conference. AACR Annual Meeting 2021. Virtual, US.
2021. Rethinking cancer and health in light of the microbiome. Conference. AAP/ASCI/APSA. Virtual, US.
2021. The role of the gut and tumor microbiome in cancer. Conference. Cell Press Beijing. Virtual, US.
2021. How to get the immune system to beat cancer'. Conference. How to get the immune system to beat cancer'. Virtual, US.
2021. The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy. Conference. Peerview. Virtual, US.
2021. The Microbiome and Immunotherapy. Conference. The Microbiome and Immunotherapy. Virtual, US.
2021. Keynote Speaker: Understanding responses to cancer therapy: the tissue is the issue, but the scoop is in the poop". Conference. MRA. Virtual, US.
2020. The role of B cells and TLS in immunotherapy response. Conference. The role of B cells and TLS in immunotherapy response. Virtual, US.
2020. The role of the gut and tumor microbiome in melanoma. Conference. SMR. Virtual, US.
2020. B-cells - why is immunotherapy not effective for some patients with metastatic melanoma and kidney cancer?. Conference. B-cells - why is immunotherapy not effective for some patients with metastatic melanoma and kidney cancer?. Virtual, US.
2020. The microbiome and its impact on molecular treatment decisions in cancer. Conference. The microbiome and its impact on molecular treatment decisions in cancer. Virtual, US.
2020. The role of diet and the gut microbiota in cancer immunotherapy response. Conference. The role of diet and the gut microbiota in cancer immunotherapy response. Virtual, US.
2020. Diet, the Microbiome and Immunotherapy Response. Conference. ASCO20 Virtual Education Program. Virtual, US.
2019. The role of the microbiome in response and toxicity to therapy. Conference. 6th Annual Microbiome Symposium. Philadelphia, PA, US.
2019. The microbiome as a biomarker of response and toxicity to cancer therapy. Conference. The microbiome as a biomarker of response and toxicity to cancer therapy. New York, NY, US.
2019. Targeting Tumor Heterogeneity. Conference. The New York Academy of Sciences. New York, NY, US.
2019. Understanding the Role of Microbiome in Cancer Immunotherapy. Conference. Microbiome Conference 2019. Boston, MA, US.
2019. The role of the microbiome in response and toxicity to cancer therapy. Conference. 2019 NIH-AACR Cancer, Autoimmunity, and Immunology Conference. Bethesda, MD, US.
2019. Gut Microbiome: Cancer, immunity and Cancer Immunotherapy. Conference. Tucson Symposium 2019. Tucson, AZ, US.
2019. Prediction of Risk and Response and Deploying the Whole Immunotherapy Arsenal. Conference. AACR Annual Meeting 2019. Atlanta, GA, US.
2019. Modulating the Gut Microbiome to Enhance Responses to Immunotherapy. Conference. American Society of Clinical Oncology (ASCO) 2019 Meeting. Atlanta, GA, US.
2019. Controversies in the Treatment of Stage III Melanoma. Conference. SSO symposium 2019 Meeting. San Diego, CA, US.
2019. Progress and Promise with Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues with Checkpoint Inhibitors as Adjuvant Therapy. Conference. CME platform & SSO symposium 2019 Meeting. San Diego, CA, US.
2019. The immune landscape and cancer therapy. Conference. The Tumour Cell: Plasticity, Progression and Therapy. New York, NY, US.
2019. General session 8: Targeting the Microbiome in Cancer Therapy, Modulating the Gut Microbiome in Cancer Therapy. Conference. 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, CA, US.
2019. Immune Mechanisms Influencing Checkpoint Therapy. Conference. Immune Mechanisms Influencing Checkpoint Therapy. Breckenridge, CO, US.
2019. Understanding the role of the microbiome of in cancer immunotherapy. Conference. 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine. Maui, HI, US.
2019. Skin Deep: Dermatologic/Surgical Considerations in Melanoma. Conference. 15th Annual International Symposium on Melanoma PER’s Melanoma. New York, NY, US.
2019. Plenary Session: The role of the microbiome in the response to immunotherapy: The "scoop is in the poop". Conference. 17th Oncology Update: Advances and Controversies. Breckenridge, CO, US.
2018. PS 01 - Presidential Symposium Session I - The Radiation Oncology/Immunotherapy Interface/What is the Potential Application in Radiation Oncology?. Conference. ASTRO 60th Annual Meeting. San Antonio, TX, US.
2018. The role of the microbiome in response to cancer therapy. Conference. 4th HIV Microbiome Workshop 2018. Rockville, MD, US.
2018. Understanding responses to cancer immunotherapy: The tissue is the issue, but the scoop is in the poop. Conference. YCIO Symposium. New Haven, CT, US.
2018. Targeting the gut and tumor microbiome in response and toxicity to cancer therapy. Conference. 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. New York, NY, US.
2018. The role of the gut microbiome in response to immunotherapy. Conference. 3rd annual Rational Combinations 360°. Philadelphia, PA, US.
2018. Understanding Responses To Cancer Therapy: The Tissue Is the Issue, but the Scoop Is in the Poop. Conference. AACR Molecular Biology in Clinical Oncology Workshop. Snowmass Village, CO, US.
2018. Session 2: Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Conference. The 33rd Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy. Aspen, CO, US.
2018. The Microbiome and Response to Melanoma Therapy. Conference. Noreen O’Neill Melanoma Research Symposium. Philadelphia, PA, US.
2018. The role of the gut microbiome in response and toxicity to immune checkpoint blockade. Conference. Federation of Clinical Immunology Societies (FOCIS). San Francisco, CA, US.
2018. Harnessing Microbiology to Treat Cancer. Conference. American Society for Microbiology. Atlanta, GA, US.
2018. Understanding Response and Resistance to Cancer Therapy through Translational Research. Conference. Dana-Farber Cancer Institute: Seminars in Oncology. Boston, MA, US.
2018. Biomakers to monitor disease response. Conference. 2018 Annual ASCO Meeting. Chicago, IL, US.
2018. Antibodies for Cancer Therapies. Conference. 14th Annual PEGS Boston. Boston, MA, US.
2018. Raising the tail in cancer immunotherapy: the tissue is the issue - but the scoop is in the poop. Conference. American Association for Cancer Research Rational Combination Therapies in Immune-oncology. Chicago, IL, US.
2018. Profiling the microbiome to predict immunotherapy efficacy. Conference. 2018 MRA Scientific Retreat. Washington, DC, US.
2018. S002- Melanoma and Mimics: New Diagnostic and Treatment Modalities/Update on adjuvant therapy in melanoma. Conference. AAD 2018 Congress. San Diego, CA, US.
2018. Analyzing the Microbiome and Biomarkers for Patient Selection. Conference. Physicians' Education Resource. New York, NY, US.
2018. Stand Up to Cancer Scientific Summit 2018. Conference. AACR. San Monica, CA, US.
2018. Precision Medicine World Conference. Conference. The Microbiome in Cancer Therapy. Mountainview, CA, US.
2017. Influence of Gut Microbiome upon PD1/Immuno-Oncology Responses. Conference. Influence of Gut Microbiome upon PD1/Immuno-Oncology Responses. National Harbor, MD, US.
2017. The extreme personalization potential in Microbiome and Immunotherapy. Conference. World Precision Medicine Congress USA 2017. Washington, DC, US.
2017. Understanding Resistance to Cancer Therapy: from bedside to bench and back again. Conference. Understanding Resistance to Cancer Therapy: from bedside to bench and back again. Florence, Italy, US.
2017. Better living through biomarkers in cancer therapy: the tissue is the issue, but the scoop is in the poop”. Conference. Forbeck Foundation Meeting. Boston, MA, US.
2017. Better living through biomarkers in cancer therapy: the tissue is the issue, but the scoop is in the poop. Conference. ECOG-ACRIN. Washington, DC, US.
2017. Deciphering Biomarkers and Mechanisms of Stromal-Mediated Drug Responses and Resistance. Conference. Deciphering Biomarkers and Mechanisms of Stromal-Mediated Drug Responses and Resistance. Washington, DC, US.
2017. Resistance to Immunotherapy, Mechanisms of Resistance to Immunotherapy in Melanoma. Conference. Resistance to Immunotherapy, Mechanisms of Resistance to Immunotherapy in Melanoma. Orlando, FL, US.
2017. News from the field – what’s going well and what’s to be done?. Conference. MRA Ninth Annual Scientific Retreat. Washington, DC, US.
2016. Understanding the Heterogeneity and Dynamics of Anti-Tumor Responses, and the Critical Role of Surgeons in Driving Such Studies. Conference. Human Genomics and Personalized Medicine in Surgical Practice. Washington, DC, US.
2016. Understanding the kinetics of response and mechanisms of therapeutic resistance in immune checkpoint blockade. Conference. Understanding the kinetics of response and mechanisms of therapeutic resistance in immune checkpoint blockade. Boston, MA, US.
2016. Understanding the heterogeneity and dynamics of the anti-tumor immune response. Conference. Understanding the heterogeneity and dynamics of the anti-tumor immune response. Breckenridge, CO, US.
2015. Understanding responses to therapy: the tissue is the issue. Conference. Understanding responses to therapy: the tissue is the issue. National Harbor, MD, US.
2015. Targeted Therapy meets Immunotherapy. Conference. Targeted Therapy meets Immunotherapy. Hilton Head Island, SC, US.
2015. Impact of TKIs on the tumor microenvironment. Conference. DAVA Oncology. Pasadena, CA, US.
2015. Immune effects of targeted therapy and implications for combination strategies. Conference. Immune effects of targeted therapy and implications for combination strategies. Philadelphia, PA, US.
2015. Therapeutic targeting and monitoring tumor immunity in melanoma. Conference. Therapeutic targeting and monitoring tumor immunity in melanoma. Philadelphia, PA, US.
2015. Melanoma Research Alliance: Understanding responses to therapy and rationale for combination strategies. Conference. Melanoma Research Alliance: Understanding responses to therapy and rationale for combination strategies. Washington, DC, US.
2015. Differential Leucocyte Profiles in Melanoma Progressing on Targeted Therapy or Immunotherapy. Conference. Differential Leucocyte Profiles in Melanoma Progressing on Targeted Therapy or Immunotherapy. Seattle, WA, US.
2014. Understanding responses in melanoma therapy: the tissue is the issue. Conference. Understanding responses in melanoma therapy: the tissue is the issue. Boston, MA, US.
2014. Effects of Targeted Therapies on the Immune system. Conference. Effects of Targeted Therapies on the Immune system. National Harbor, MD, US.
2014. Combining Targeted Therapy and Immune Checkpoint Blockade to Improve Responses. Conference. Combining Targeted Therapy and Immune Checkpoint Blockade to Improve Responses. Philadelphia, PA, US.
2014. Immunologic Effects of BRAF Inhibitor Therapy. Conference. Immunologic Effects of BRAF Inhibitor Therapy. Dallas, TX, US.
2013. Effect of BRAF Inhibition on PD-L1 Expression. Conference. Effect of BRAF Inhibition on PD-L1 Expression. Coral Gables, FL, US.
2013. Evidence for Potential Synergy of BRAF-Targeted Therapy and Immunotherapy for Metastatic Melanoma. Conference. Evidence for Potential Synergy of BRAF-Targeted Therapy and Immunotherapy for Metastatic Melanoma. Washington, DC, US.
2012. Combined Immunotherapy and Targeted Therapy for Melanoma. Conference. Combined Immunotherapy and Targeted Therapy for Melanoma. Santa Monica, CA, US.
2011. Modern Melanoma Immunotherapy. Conference. Modern Melanoma Immunotherapy, US.

International Presentations

2022. The role of the gut and tumor microbiome in cancer. Invited. Gustave Roussy Institute. Paris, FR.
2022. Vaginal/cervical microbiota. Invited. Gustave Roussy Institute. Paris, FR.
2022. The role of the gut and tumor microbiome in cancer. Invited. Gustave Roussy Institute. Paris, FR.
2022. Targeting the microbiome to promote health and end cancer. Invited. International Alliance for Biological Standardization. Virtual, US.
2021. Microbiome transplantations versus diet. Invited. 10th World Congress of Melanoma. Virtual, US.
2021. The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy. Invited. Peerview. Virtual, US.
2020. The role of the gut and tumor microbiome in melanoma. Invited. SMR. Virtual, US.
2020. Diet, the Microbiome and Immunotherapy Response. Invited. ASCO20 Virtual Education Program. Virtual, US.
2020. Cancer Immunotherapy and the Microbiome. Invited. BIO Asia-Taiwan 2020 Online + Live. Taipei, TW.
2019. The role of the microbiome in response and toxicity to therapy. Invited. CICON - Cancer Immunotherapy Conference. Paris, FR.
2019. The role of the microbiome in cancer. Invited. Canadian Cancer Immunotherapy Consortium Annual Meeting. Virtual, CA.
2019. Microbiome and cancer - The role of the microbiome in response and toxicity to therapy. Invited. CRUK. London, GB.
2019. The role of the gut and tumor microbiome in response to cancer therapy. Invited. 31st Pezcoller Symposium. Trento, IT.
2019. Modulating the Gut Microbiome to Enhance Responses to Immunotherapy. Invited. American Society of Clinical Oncology (ASCO) 2019 Meeting. Atlanta, US.
2019. The Gut Microbiome and PD-1 Therapy in Melanoma. Invited. Keystone Symposium Conference | Cancer Metastasis. Firenze Fiera-Fortezza da Basso, Florence, IT.
2019. Microbiome Targeting and Future Strategies to improve Cancer immunotherapy. Invited. Whistler Conference Centre, Keystone Symposia Immunotherapy. Whistler, British Columbia, CA.
2019. General session 8: Targeting the Microbiome in Cancer Therapy, Modulating the Gut Microbiome in Cancer Therapy. Invited. 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, US.
2019. Skin Deep: Dermatologic/Surgical Considerations in Melanoma. Invited. 15th Annual International Symposium on Melanoma PER’s Melanoma. New York, US.
2019. Gut microbiome and response to anti-PD-1. Invited. Cells to Surgery 2019, 2nd Rotterdam Skin Cancer Congress. Rotterdam, NL.
2018. Advancing melanoma therapy through team science. Invited. SMR Annual Meeting. London, GB.
2018. Targeting the gut and tumor microbiome in response and toxicity to cancer therapy. Invited. 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. New York, US.
2018. The intestinal microbioma and the immune response. Invited. International Melanoma Meeting. Sao Paulo, BR.
2018. Role of Neoadjuvant therapy in high risk melanoma patients. Invited. International Melanoma Meeting. Sao Paulo, BR.
2018. Nature Roundtable: The Future of Medicine. Invited. Curious2018/Merck. Darmstadt, DE.
2018. Targeting immune system: immunotherapy/Insights in response to cancer therapy via reverse translation. Invited. Frontiers in Immunomodulation in Cancer. Madrid, ES.
2018. Keynote Lecture: The gut microbiome: a significant player for cancer immunotherapy?. Invited. 8th European Post-Chicago Melanoma/Skin Cancer Meeting. Munich, DE.
2018. Melanoma diagnosis and treatment 2025: my vision/Still a need for surgery and radiation therapy?. Invited. 8th European Post-Chicago Melanoma/Skin Cancer Meeting. Munich, DE.
2018. Keynote speech: The role f microbiota in response and toxicity to cancer therapy. Invited. 7th IHM Congress 2018. Killarney, IE.
2018. Biomakers to monitor disease response. Invited. 2018 Annual ASCO Meeting. Chicago, US.
2018. Analyzing the Microbiome and Biomarkers for Patient Selection. Invited. Physicians' Education Resource. New York, US.
2017. The extreme personalization potential in Microbiome and Immunotherapy. Conference. World Precision Medicine Congress USA 2017. Washington, US.
2017. Predictors of response to immune checkpoint blockade. Invited. Postgraduate Institute for Medicine. Paris, FR.
2016. Understanding response and resistance to melanoma therapy: lessons learned from mouse and man. Invited. Melanoma Bridge. Naples, IT.
2016. Understanding responses to cancer therapy: the tissue is the issue but the scoop is in the poop”. Invited. NCRI. Liverpool, GB.
2016. Understanding responded to therapy: the tissue’s the issue, but the scoop’s in the poop. Invited. Australia Melanoma Conference. Sydney, AU.
2015. Understanding immune and molecular determinants of response to melanoma therapy. Invited. Melanoma Bridge 2015. Naples, IT.
2015. Understanding the dynamics and heterogeneity of responses to melanoma therapy. Invited. Adaptive/Illumina. Marseilles, FR.
2013. BRAF Inhibition is Associated with Enhanced Antigen Expression and a More Favorable Tumor Microenvironment in Melanoma. Invited. World Congress of Melanoma. Hamburg, DE.

Formal Peers

2022. Plenary Session in Immuno-Microbio_Oncology Annual Meeting 2022. Invited. Paris, FR.
2022. The Role of the Gut and Tumor Microbiome in Cancer. Visiting. VIRTUAL, US.
2022. A holistic approach to promote health and end cancer. Invited. San Diego, CA, US.
2021. Understanding responses to cancer therapy: the tissue is the issue, the scoop is in the poop, and you are what you eat. Invited. Virtual, US.
2021. The role of the gut and tumor microbiome in cancer. Visiting. Virtual, US.
2021. Understanding responses to cancer therapy: the tissue is the issue, the scoop is in the poop, and you are what you eat. Invited. Virtual, US.
2021. Understanding responses to cancer therapy: the tissue is the issue, the scoop is in the poop, and you are what you eat. Invited. Virtual, US.
2021. Understanding responses to cancer therapy: the tissue is the issue, the scoop is in the poop, and you are what you eat. Invited. Virtual, US.
2021. Understanding responses to cancer therapy through translational research. Invited. Virtual, US.
2021. Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat. Invited. Virtual, US.
2021. Understanding responses to cancer therapy through translational research: A surgeon's perspective. Invited. Virtual, US.
2021. Understanding responses to cancer therapy: the tissue is the issue, the scoop is in the poop, and diet and hormones matter, and slides. Visiting. Virtual, US.
2021. The Role of Gut and Tumor Microbiome In Cancer. Visiting. Virtual, US.
2020. The role of the gut and tumor microbiome in cancer. Invited. Virtual, US.
2020. Understanding Responses to Cancer Therapy through Translational Research, a Surgeon’s Prospective. Invited. Virtual, US.
2020. The Role of Gut and Tumor Microbiome In Response to Cancer Therapy. Invited. Virtual, US.
2020. The role of the gut and tumor microbiome in cancer. Invited. Virtual, TX, US.
2020. Understanding responses to cancer therapy: the tissue is the issue, but the scoop is in the poop. Invited. Virtual, US.
2019. Microbiota and Cancer Therapy. Invited. Bethesda, MD, US.
2019. Understanding the complexities of response to cancer therapy: the organism as a holobiont. Invited. Palo Alto, CA, US.
2018. Microbiome and Immunotherapy. Visiting. Houston, TX, US.
2018. Understanding responses to cancer therapy: the tissue is the issue, but the scoop is in the poop”. Visiting. Boston, MA, US.
2018. ABOG Lectureship. Visiting. New Orleans, LA, US.
2018. Cancer Microbiome/The microbiome and response to cancer therapy. Invited. Stockholm, SE.
2018. Novel insights into response to melanoma therapy. Visiting. Baltimore, MD, US.
2017. Understanding responses to melanoma therapy: the tissue is the issue, but the scoop is in the poop. Visiting. Orlando, FL, US.
2016. Understanding response and resistance to melanoma therapy: lessons learned from mouse and man. Invited. Portland, OR, US.
2016. Microbiome meeting. Visiting. New York City, NY, US.
2015. Understanding Responses to Melanoma Therapy: Lessons Learned from Mouse and Man. Invited. Tampa, FL, US.
2015. Understanding Responses to Cancer Therapy: The Tissue is the Issue. Visiting. Atlanta, GA, US.
2015. Understanding Responses to Melanoma Therapy: Lessons Learned from Mouse and Man. Invited. Boston, MA, US.
2015. Understanding Responses to Melanoma Therapy: Lessons Learned from Mouse to Man. Invited. San Diego, CA, US.
2015. Understanding Responses to Melanoma Therapy: Lessons Learned from Mouse and Man. Invited. Philadelphia, PA, US.
2014. Melanoma Surgery in the Era of Improved Systemic Therapy. Invited. Porto, PT.
2014. Understanding Responses to Melanoma Therapy: The Tissue is the Issue. Invited. Tampa, FL, US.
2014. Immune Effects of BRAF Inhibitors and Implications for Combination Therapy. Invited. Porto, PT.
2014. TMEN Steering Committee Meeting. The Role of Stroma in Response and Resistance to Therapy in Melanoma: Insights Gained Through TMEN Collaborations. Invited. New York, NY, US.
2014. Unlocking the Mysteries of Response to BRAF Therapy through Biopsy. Invited. Los Angeles, CA, US.
2013. Understanding the Effects of Oncogenic BRAF on the Tumor Microenvironment Lecture. Visiting, US.
2013. Effects of BRAF Inhibition on the Tumor Microenvironment Lecture. Visiting, US.
2012. Strategies to Overcome Resistance to BRAF-Targeted Therapy in Melanoma Lecture. Visiting, US.
2012. Understanding the Effects of Oncogenic BRAF on Tumor Immunity and the Tumor Microenvironment. Invited, US.
2011. Update on Melanoma Therapeutics. Visiting, US.
2011. Exploring Immune Effects of BRAF Inhibitors Lecture. Visiting, US.
2011. Exploring Synergy of Targeted Therapy and Immunotherapy for Melanoma Lecture. Visiting, US.
2011. Melanoma 2011: Update to Healthcare Providers. Invited, US.
2010. Primary Melanoma Management Lecture. Visiting, US.
2010. Immunotherapy for Melanoma: Updates and New Directions. Visiting, US.
2009. Primary Melanoma Management Lecture. Visiting, US.
2009. Immunotherapeutic and Epigenetic Approaches Targeting Cancer-Testis Antigens in Pancreatic Cancer Lecture. Visiting, US.

Less

Grant & Contract Support

Date:	2026 - 2030
Title:	Evaluating Mediterranean Diet Intervention among Medically Underserved Men with Prostate Cancer
Funding Source:	AMERICAN CANCER SOCIETY
Role:	PI
ID:	1504710

Date:	2025 - 2028
Title:	Targeting Novel Host-Intrinsic and Extrinsic Factors to Enhance Melanoma Therapy Response
Funding Source:	Dr Miriam and Sheldon G Adelson
Role:	PI
ID:	04-7023433; 00016133

Date:	2025 - 2029
Title:	Bile acids as a mediator of the diet-microbiome-immune axis
Funding Source:	V FOUNDATION
Role:	PI
ID:	T2025-005

Date:	2025 - 2030
Title:	Neoadjuvant SEMA4D/ICB in Melanoma
Funding Source:	EMORY UNIVERSITY
Role:	PI
ID:	1R01CA300792-01

Date:	2025 - 2030
Title:	The role of oral microbiota in metastatic brain tumors
Funding Source:	NCI
Role:	PI
ID:	K99CA296780

Date:	2024 - 2027
Title:	ME230008: The Role of Microbiota and Microbial Extracellular Vesicles in Metastatic Dormancy in Melanoma
Funding Source:	DoD
Role:	PI
ID:	FP00020694

Date:	2024 - 2029
Title:	Dietary intervention to modulate the microbiome and immune response
Funding Source:	CPRIT
Role:	PI
ID:	RP240557

Date:	2024 - 2029
Title:	Prebiotic Diet Intervention to Enhance the Microbiome and Immunotherapy Response in Melanoma
Funding Source:	NCI
Role:	PI
ID:	R01CA291965

Date:	2024 - 2028
Title:	Neoadjuvant Ipilimumab/Nivolumab + Microbiota-Directed Prebiotic Dietary Intervention To Optimize Immune Response in Melanoma
Funding Source:	American Cancer Society
Role:	PI
ID:	RSG-24-1255125-01-CPHP

Date:	2024 - 2029
Title:	Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy
Funding Source:	NCI
Role:	PI
ID:	R01 CA 282027

Date:	2024 - 2029
Title:	Targeting the Gut Microbiome to Inhibit Melanoma Lymph Node Metastases
Funding Source:	NCI
Role:	PI
ID:	1 R01 CA 289456 - 01

Date:	2023 - 2025
Title:	Identifying immune biomarkers of resistance to neoadjuvant immune-checkpoint blockade in soft tissue sarcoma
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2023 - 2028
Title:	Prebiotic dietary intervention in melanoma patients on immunotherapy
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2023 - 2026
Title:	Delineating strategies to enhance immunotherapy response via microbial targeting of tertiary lymphoid structures / B cells
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2022 - 2024
Title:	New Elucidating the Role of the Gut and Tumor Microbiome in Malignant Glioma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT13552668

Date:	2022 - 2025
Title:	Delineating germline, tumor and extrinsic factors driving mucosal melanoma risk and response
Funding Source:	Department of Defense (DOD)
Role:	Co-PI
ID:	ME210289

Date:	2022 - 2026
Title:	ME210289P2 Delineating Germline, Tumor and Extrinsic Factors Driving Mucosal Melanoma Risk and Response
Funding Source:	DoD
Role:	Co-PI
ID:	W81XWH2210975; 00014720

Date:	2022 - 2028
Title:	MD Anderson Endometrial Cancer SPORE
Funding Source:	NIH/NCI
Role:	Director

Date:	2022 - 2025
Title:	Harnessing tertiary lymphoid structure function for improved immunotherapeutic strategies in cancer patients
Funding Source:	Mark Foundation for Cancer Research
Role:	Co-I

Date:	2021 - Present
Title:	Targeting Bacteroides intestinalis to reduce immunotherapy associated toxicity
Funding Source:	SNIPR Biome
Role:	PI

Date:	2021
Title:	Diet and the gut microbiome in hepatocellular carcinoma patients initiating immunotherapy: new targets to improve clinical outcomes
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA266267-01

Date:	2021 - Present
Title:	Dr. R Lee Clark Professorship
Funding Source:	Dr R Lee Clark Professorship
Role:	PI

Date:	2021 - 2022
Title:	Assessing spatial configuration and function of bacteria in pancreatic cancer and metastasis
Funding Source:	Robert L. Fine Cancer Research
Role:	Co-I

Date:	2021 - 2023
Title:	Integrating microbiome and organoid analyses of patient cohorts for immuno-oncology therapeutic development
Funding Source:	SU2C Convergence Grant
Role:	PI

Date:	2020 - 2025
Title:	Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R37CA237384-01A1

Date:	2020 - 2025
Title:	Diet and the gut microbiome in hepatocellular carcinoma prognosis and therapeutic response
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2020 - 2023
Title:	Targeting B cells to enhance responses to immune checkpoint blockade
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP200574

Date:	2020 - 2024
Title:	Modulating the gut-tumor microbial axis to reverse pancreatic cancer immunosuppression
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP200173

Date:	2020 - 2023
Title:	Exploring molecular & immune mechanisms of response and resistance to neoadjuvant checkpoint blockade in patients with surgically resectable soft tissue sarcoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator

Date:	2020 - 2021
Title:	Controlled high-fiber dietary intervention to modulate gut microbiome in melanoma patients receiving immunotherapy
Funding Source:	Mark Foundation for Cancer Research
Role:	Key
ID:	FP00008817

Date:	2019 - 2022
Title:	Modulating pancreatic cancer immunosuppression by fecal microbial transplants
Funding Source:	V Foundation
Role:	Co-I
ID:	T2019-007

Date:	2019 - 2024
Title:	The University of Texas MD Anderson Cancer Center SPORE in Melanoma- Core 1
Funding Source:	NIH/NCI
Role:	PI
ID:	P50 CA221703

Date:	2019 - 2021
Title:	Liquid biopsy of microRNAs as biomarkers and targets of drug response in melanoma
Funding Source:	Sister Institution Network Fund (SINF)
Role:	PI

Date:	2019 - 2024
Title:	Loxl2 and H3K4 methylation as effectors of anti-PD1 response in melanoma
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1 R01 CA231146 01

Date:	2019 - Present
Title:	Nath Family Foundation Melanoma Research
Funding Source:	Nath Family Foundation Melanoma Research
Role:	PI

Date:	2018 - 2021
Title:	Diet, Mental Health, and the Microbiome in Response to Immunotherapy
Funding Source:	Melanoma Research Foundation
Role:	Co-I

Date:	2018 - 2023
Title:	(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA219896-01A1

Date:	2018 - 2023
Title:	Training of Academic Surgical Oncologists
Funding Source:	NIH/NCI
Role:	Program Director
ID:	T32 CA009599

Date:	2017 - 2019
Title:	Understanding and Improving Outcomes in Refractory Melanoma
Funding Source:	Adelson Medical Research Foundation
Role:	Co-I

Date:	2017 - 2023
Title:	Translational Cancer Immune Monitoring and Analysis Center (TCIMAC)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U24CA224285-01

Date:	2017 - 2020
Title:	Delineating the Role of the Microbiome in Modulating Tumor and Host Immunity
Funding Source:	American Association for Cancer Research (AACR)
Role:	PI
ID:	SU2C-AACR-IRG-19-17

Date:	2017 - 2020
Title:	Epigenetic Effectors of Responses to Immune Checkpoint Blockade Agents
Funding Source:	Melanoma Research Alliance
Role:	Co-I

Date:	2017 - 2019
Title:	Delineating the Role of the Gut Microbiome in Modulating Responses to Immune Check Point Blockage in Melanoma
Funding Source:	Andrew Sabin Award
Role:	PI
ID:	117205-Sabin

Date:	2017 - Present
Title:	Nath Family Endowment
Funding Source:	Nath Family Endowment
Role:	Investigator
ID:	600377-80-120726-19

Date:	2016 - 2019
Title:	Developing Effective Immunotherapeutic Strategies for Advanced Uveal Melanoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP170317

Date:	2016 - 2018
Title:	Unlocking Tumor Immunophenotype in Responders versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2016 - 2021
Title:	NO TITLE PROVIDED
Funding Source:	Parker Institute for Cancer Immunotherapy
Role:	PI
ID:	Parker Research Fund

Date:	2016 - 2020
Title:	Understanding the immune-biology of checkpoint inhibitors to develop new strategies for therapy
Funding Source:	DOD Translational Team Science Award
Role:	PI
ID:	W81XWH-16-1-0121

Date:	2016 - 2019
Title:	Identifying somatic and microbial neo-antigens associated with melanoma response
Funding Source:	Melanoma Research Alliance Team Science Award
Role:	Co-PI

Date:	2016 - 2017
Title:	Exploring the role of the microbiome in response to immune-checkpoint blockade in melanoma
Funding Source:	Knowledge GAP, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2016 - 2018
Title:	Identifying microbial determinants of response and resistance to targeted therapy in Melanoma
Funding Source:	Sister Institution Network Fund Grants (SINF)
Role:	PI

Date:	2015 - 2016
Title:	Analyses of tumor-derived circulating exosomes in therapeutic response and resistance in melanoma
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2015 - 2016
Title:	Rising STARS Award
Funding Source:	The University of Texas System
Role:	PI

Date:	2015 - 2016
Title:	Regents' Health Research Scholar Award
Funding Source:	The University of Texas System
Role:	PI

Date:	2015 - 2019
Title:	Exploring molecular and immune mechanisms of response and resistance to combined BRAF/MEK inhibition in patients with high-risk resectable metastatic melanoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP150030

Date:	2015 - 2016
Title:	Exploring differential immunophenotypes in uveal melanoma and their relationship to treatment response
Funding Source:	UTMDACC IRG (Patel)
Role:	Collaborator

Date:	2014 - 2015
Title:	NO TITLE PROVIDED
Funding Source:	Adaptive Biotechnologies
Role:	PI
ID:	ADAP-NCI-261201300037C

Date:	2014 - 2015
Title:	An immune repertoire deep sequencing companion diagnostic for ipilimumab
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	ADAP-NCI-261201300037C

Date:	2014 - 2019
Title:	Exploring the role of the tumor microbiome in response and resistance to molecularly targeted therapy for melanoma
Funding Source:	US - Israel Binational Science Foundation
Role:	PI

Date:	2014 - 2015
Title:	Epigenome-based biomarkers of response and resistance to immune checkpoint inhibitors
Funding Source:	NIH/NCI
Role:	PI
ID:	P50CA093459

Date:	2014 - 2016
Title:	Understanding the role of the tumor microbiome in resistance to targeted therapy in melanoma
Funding Source:	IRG - The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2014 - 2015
Title:	Studies on the mechanism(s) of resistance to RAF inhibitor-based therapies
Funding Source:	Melanoma Research Alliance
Role:	Co-PI

Date:	2013 - 2018
Title:	Exploring the interplay between oncogenic mutations and tumor immunity in response and resistance to targeted therapy and immunotherapy for melanoma
Funding Source:	The University of Texas MD Anderson Cancer Center Institutional Start-up
Role:	PI
ID:	600377-30-112074-15

Date:	2013 - 2014
Title:	Analysis of exosomes in melanoma patients as a function of therapeutic response and resistance to BRAF-targeted therapy
Funding Source:	The University of Texas MD Anderson Cancer Center Melanoma SPORE - Career Development Program Award
Role:	Collaborator

Date:	2013 - 2014
Title:	Exploring the role of the host microbiome in response and resistance to molecularly targeted therapy for melanoma
Funding Source:	The University of Texas MD Anderson Cancer Center Melanoma SPORE - Career Development Program Award
Role:	Mentor
ID:	5P50CA093459-09

Date:	2013 - 2014
Title:	Cancer Center Support Grant
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	P30CA016672

Date:	2012 - 2014
Title:	Analysis of the kinetics and effects of vemurafenib on intratumoral and host immunity in patients with advanced BRAFV600 mutant Melanoma: Implications for combination with immunotherapy
Funding Source:	Melanoma Research Alliance Team Science Award
Role:	PI

Date:	2012 - 2018
Title:	Melanoma Tissue Donation Program
Funding Source:	Kenedy Memorial Foundation
Role:	PI

Date:	2011 - 2013
Title:	Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Funding Source:	MGH Vaccine and Immunotherapy Center
Role:	PI

Date:	2011 - 2016
Title:	Role of tumor stroma in therapeutic response and resistance. Co-leader – Core A: Clinically Annotated Human Melanoma for TMEN Research
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5U54CA163125-04

Date:	2011 - 2016
Title:	Role of tumor stroma in therapeutic response and resistance. Co-leader – Project 2: Immune Regulatory Pathways in BRAF Targeted Therapy in Melanoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5U54 CA163125-04

Date:	2010 - 2011
Title:	Immunotherapeutic and Epigenetic Approaches Targeting the MAGE-A3 Antigen in the Treatment of Pancreatic Cancer
Funding Source:	Warshaw Institute for Pancreatic Research
Role:	PI

Date:	2010 - 2011
Title:	Exploring Cooperative Therapeutic Strategies in Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
Funding Source:	Claflin Distinguished Scholar Award
Role:	PI

Date:	2008 - 2009
Title:	Immunotherapeutic and Epigenetic Approaches Targeting Cancer-
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	P50CA127003

Date:	2008 - 2014
Title:	Immunotherapy for melanoma
Funding Source:	Schlesinger Gift Fund, Massachusetts General Hospital
Role:	PI

Date:	1994 - 2028
Title:	Training of Academic Surgical Oncologists
Funding Source:	NCI
Role:	PI
ID:	T32CA009599

Selected Publications

Peer-Reviewed Articles

Galeano Niño, JL, Ponath, F, Ajisafe, VA, Becker, CR, Kempchinsky, AG, Zepeda Rivera, M, Gomez, JA, Wu, H, Terrazas, JG, Bouzek, H, Cromwell, E, Chanana, P, Wong, M, Damania, A, White, MG, You, YN, Kopetz, S, Ajami, NJ, Wargo, J, Johnston, CD, Bullman, S. Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer cell 44(1):166-186.e16, 2026. e-Pub 2026. PMID: 41106380.
Rapisuwon, S, Slingluff, CL, Wargo, J, Sullivan, RJ, Izar, B, Lin, JR, Mauldin, IS, Olson, WC, Tran, CA, Schwartzman, GH, Gibney, GT, Alrefaie, W, Atkins, MB. Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma. Cancer medicine 15(1), 2026. e-Pub 2026. PMID: 41514118.
Robert, M, Saha, S, Dizman, N, Rohlfs, ML, Sirmans, E, Simon, JM, Amaria, RN, Glitza, IC, Tawbi, H, Davies, MA, Ikeguchi, AP, Basen-Engquist, KM, Schadler, KL, Roth, M, Song, W, Zhang, X, Ajami, NJ, Cohen, L, Wargo, J, Peterson, CB, McQuade, JL, Daniel-MacDougall, CR. Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors. Nutrients 18(1), 2026. e-Pub 2026. PMID: 41515159.
Dimitriou, F, Wu, X, Nagarajan, P, Glitza, IC, Zhao, L, Ning, J, Patel, SP, Wargo, J, Futreal, A, Woodman, SE, McQuade, JL, Esmaeli, B. Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 41261164.
Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
Grippin, A, Marconi, C, Copling, S, Li, N, Braun, C, Rooney, M, Schrank, B, Gladish, G, Vaporciyan, AA, Johns, AC, Subbiah, IM, Aloia, TA, Wu, J, Wu, CC, Woodman, SE, Weinstein, JN, Tawbi, H, Shete, S, Scheet, PA, Ravi, V, Palaskas, NL, Nates, JL, Muthu, M, Musunuru, TN, McEnery, KW, Litton, J, John, TM, Jaffray, D, Hutcheson, KA, Gunther, J, Godoy, M, Futreal, A, French, KE, Draetta, G, Dabaja, BS, Crommett, JW, Cata, JP, Brock, K, Beird, H, Aaroe, AE, Lee, JJ, Sun, R, Sharma, P, Tran, HT, Zhang, J, Gibbons, DL, Wargo, J, Heymach, JV, Jiang, W, Lin, SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
Morad, G, Damania, A, Melendez, B, Singh, BB, Veguilla, FJ, Soto, RA, Hoballah, YM, Sahasrabhojane, P, Wong, M, Ahmed, M, Rico, R, Lewis, KN, Wani, K, Shamsutdinova, D, Lazcano Segura, RN, Ingram, D, Goethe, E, Day, A, Flores, I, McDaniel, L, Chelvanambi, M, Johnson, S, Dimitriou, F, Gupta, P, Oberai, S, Zal, MA, Doss, P, Jamal, MA, Hayase, E, Wathoo, C, Norberg, L, Jenkins, SL, Nass, S, Gumin, J, Long, L, Yang, J, Bradley, GR, Bekal, MP, Dono, A, Pichardo-Rojas, PS, Andrewes, S, Ballester, L, Losh, JS, Liang, J, Huo, L, Nielsen, D, Parker Kerrigan, BC, Brastianos, PK, Fowlkes, NW, Chang, C, Jenq, RR, Gomez-Manzano, C, Huse, J, Davies, MA, Lazar, A, Bhat, KP, Tandon, N, Esquenazi, Y, Peterson, CB, Puduvalli, VK, Lang Jr, FF, Johnston, CD, Bullman, S, Ajami, NJ, Ferguson, SD, Wargo, J. Microbial signals in primary and metastatic brain tumors. Nature medicine 31(11):3675-3688, 2025. e-Pub 2025. PMID: 41238915.
Burton EM, Milton DR, Tetzlaff MT, Wani K, Ross MI, Postow MA, Lazcano R, Glitza IC, Wong MK, Patel SP, Diab A, Gershenwald JE, McQuade JL, Betof Warner A, Prieto VG, Lee JE, Goepfert RP, Fisher SB, Song A, Malke J, Simon JM, Ariyan C, Torres-Cabala CA, Davies MA, Lazar A, Wargo JA, Tawbi HA, Amaria RN. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol 43(26):2856-2862, 2025. e-Pub 2025. PMID: 40638872.
Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallon de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature, 2025. e-Pub 2025. PMID: 40836096.
Hadjigeorgiou AG, Harkos C, Mishra AK, Morad G, Johnson SB, Ajami NJ, Wargo JA, Munn LL, Stylianopoulos T, Jain RK. Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy. Cancer Res 85(16):3139-3155, 2025. e-Pub 2025. PMID: 40439571.
Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clin Cancer Res 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Lastrapes M, Liu H, Yuan Z, Wang C, Nie H, Jean S, Montaner LJ, Hou J, Patel A, Patel S, Fellman B, Yuan Y, Sun B, Pandurengan RK, Cuentas ERP, Celestino J, Liu Y, Liu J, Hillman RT, Westin SN, Sood AK, Soliman PT, Shafer A, Meyer LA, Gershenson DM, Vining D, Ganeshan D, Lu K, Wargo JA, Peng W, Zhang R, Wang L, Jazaeri AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
Ayabe RI, Seo YD, Melendez B, Fields BC, Diggs LP, Lazcano R, Singh BB, Wani K, Ingram D, Johnson S, Chelvanambi M, Hudgens C, Hernandez SD, Ajami NJ, Wargo JA, Lazar AJ, Knafl M, Woodman S, Halperin DM, Estrella JS, Maxwell JE. Cancer Testis Antigen Expression Correlates With Immune Activation and Survival in Small Bowel Neuroendocrine Tumors. JCO Precis Oncol 9:e2500107, 2025. e-Pub 2025. PMID: 40638874.
Ballerini M, Galie S, Tyagi P, Catozzi C, Raji H, Nabinejad A, Macandog ADG, Cordiale A, Slivinschi BI, Kugiejko KK, Freisa M, Occhetta P, Wargo JA, Ferrucci PF, Cocorocchio E, Segata N, Vignati A, Morgun A, Deleidi M, Manzo T, Rasponi M, Nezi L. A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma. Nat Biomed Eng 9(6):967-984, 2025. e-Pub 2025. PMID: 39939548.
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. Editorial Expression of Concern: A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 641(8062):E7, 2025. e-Pub 2025. PMID: 40275110.
Weathers SP, Li X, Zhu H, Damania AV, Knafl M, McKinley B, Lin H, Harrison RA, Majd NK, O'Brien BJ, Penas-Prado M, Loghin M, Kamiya-Matsuoka C, Yung WKA, Solis Soto LM, Maru DM, Wistuba I, Parra Cuentas ER, Hernandez S, Futreal A, Wargo JA, Schulze K, Darbonne WC, Ajami NJ, Woodman SE, de Groot JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial. Nat Commun 16(1):3950, 2025. e-Pub 2025. PMID: 40289138.
Massara M, Ballabio M, Dolfi B, Morad G, Wischnewski V, Lamprou E, Lourenco J, Claudinot S, Gallart-Ayala H, Mendez RS, Kauzlaric A, Fournier N, Damania AV, Wong MC, Ivanisevic J, Ajami NJ, Wargo JA, Joyce JA. The bacterial microbiome modulates the initiation of brain metastasis by impacting the gut-to-brain axis. iScience 28(2):111874, 2025. e-Pub 2025. PMID: 39995854.
Rosario SR, Long MD, Chilakapati S, Gomez EC, Battaglia S, Singh PK, Wang J, Wang K, Attwood K, Hess SM, McGray AJR, Odunsi K, Segal BH, Paragh G, Liu S, Wargo JA, Zsiros E. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat Commun 15(1):10609, 2024. e-Pub 2024. PMID: 39638782.
Farias RM, Jiang Y, Levy EJ, Hwang C, Wang J, Burton EM, Cohen L, Ajami N, Wargo JA, Daniel CR, McQuade JL. Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer 24(1):1493, 2024. e-Pub 2024. PMID: 39633321.
Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H. Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment. Cancer Immunol Res 12(12):1736-1752, 2024. e-Pub 2024. PMID: 39269772.
Bowen MB, Melendez B, Zhang Q, Yang RK, Fellman BM, Lawson BC, Adjei NN, Celestino J, Wani KM, Singh B, Urbauer DL, Lazar AJ, Lu KH, Wargo JA, Westin SN, Yates MS. Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res 30(22):5073-5082, 2024. e-Pub 2024. PMID: 38922360.
Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study. Vaccines (Basel) 12(9), 2024. e-Pub 2024. PMID: 39340100.
Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Xiao Y, Fan C, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Enkhbayar A, Mohammed A, Schmiester M, King KY, Britton RA, Reddy P, Wong MC, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Katsamakis Z, Smith N, Burgos da Silva M, Ponce DM, Peled JU, van den Brink MRM, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
Boe RH, Triandafillou CG, Lazcano R, Wargo JA, Raj A. Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance. bioRxiv, 2024. e-Pub 2024. PMID: 39005406.
Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins J, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov 14(7):1161-1175, 2024. e-Pub 2024. PMID: 38588588.
Mishra AK, Mahmud I, Lorenzi PL, Jenq RR, Wargo JA, Ajami NJ, Peterson CB. TARO: tree-aggregated factor regression for microbiome data integration. Bioinformatics 40(6), 2024. e-Pub 2024. PMID: 38788190.
Belotserkovsky I, Stabryla LM, Hunter M, Allegretti J, Callahan BJ, Carlson PE, Daschner PJ, Goudarzi M, Guyard C, Jackson SA, Rao K, Servetas SL, Sokol H, Wargo JA, Novick S. Standards for fecal microbiota transplant: Tools and therapeutic advances. Biologicals 86:101758, 2024. e-Pub 2024. PMID: 38518435.
Wargo JA, Ajami NJ, Daniel-MacDougall CR. Jennifer A. Wargo, Nadim J. Ajami, and Carrie R. Daniel-MacDougall. Cell Rep Med 5(4):101509, 2024. e-Pub 2024. PMID: 38631287.
Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
Liu Q, Adhikari E, Lester DK, Fang B, Johnson JO, Tian Y, Mockabee-Macias AT, Izumi V, Guzman KM, White MG, Koomen JM, Wargo JA, Messina JL, Qi J, Lau EK. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun 15(1):1148, 2024. e-Pub 2024. PMID: 38326303.
Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine 98:104873, 2023. e-Pub 2023. PMID: 38040541.
Jain R, Hadjigeorgiou A, Harkos C, Mishra A, Morad G, Johnson S, Ajami N, Wargo J, Munn L, Stylianopoulos T. Dissecting the Impact of the Gut Microbiome on Cancer Immunotherapy. Res Sq, 2023. e-Pub 2023. PMID: 38076985.
Colbert LE, El Alam MB, Wang R, Karpinets T, Lo D, Lynn EJ, Harris TA, Elnaggar JH, Yoshida-Court K, Tomasic K, Bronk JK, Sammouri J, Yanamandra AV, Olvera AV, Carlin LG, Sims T, Delgado Medrano AY, Napravnik TC, O'Hara M, Lin D, Abana CO, Li HX, Eifel PJ, Jhingran A, Joyner M, Lin L, Ramondetta LM, Futreal AM, Schmeler KM, Mathew G, Dorta-Estremera S, Zhang J, Wu X, Ajami NJ, Wong M, Taniguchi C, Petrosino JF, Sastry KJ, Okhuysen PC, Martinez SA, Tan L, Mahmud I, Lorenzi PL, Wargo JA, Klopp AH. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell 41(11):1945-1962.e11, 2023. e-Pub 2023. PMID: 37863066.
Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
Mishra AK, Mahmud I, Lorenzi PL, Jenq RR, Wargo JA, Ajami NJ, Peterson CB. TARO: tree-aggregated factor regression for microbiome data integration. bioRxiv, 2023. e-Pub 2023. PMID: 37904958.
White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy. Ann Surg 278(4):538-548, 2023. e-Pub 2023. PMID: 37465976.
Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL, Nelson KC. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol 159(10):1076-1084, 2023. e-Pub 2023. PMID: 37647056.
Bastos G, Holmes JT, Ross JM, Rader AM, Gallimore CG, Wargo JA, Peterka DS, Hamm JP. Top-down input modulates visual context processing through an interneuron-specific circuit. Cell Rep 42(9):113133, 2023. e-Pub 2023. PMID: 37708021.
Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol 34(9):796-805, 2023. e-Pub 2023. PMID: 37414216.
Goyal Y, Busch GT, Pillai M, Li J, Boe RH, Grody EI, Chelvanambi M, Dardani IP, Emert B, Bodkin N, Braun J, Fingerman D, Kaur A, Jain N, Ravindran PT, Mellis IA, Kiani K, Alicea GM, Fane ME, Ahmed SS, Li H, Chen Y, Chai C, Kaster J, Witt RG, Lazcano R, Ingram DR, Johnson SB, Wani K, Dunagin MC, Lazar AJ, Weeraratna AT, Wargo JA, Herlyn M, Raj A. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature 620(7974):651-659, 2023. e-Pub 2023. PMID: 37468627.
Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel SH, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JE. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol 128(2):313-321, 2023. e-Pub 2023. PMID: 37010038.
Seo YD, Ajami N, Wargo JA. Using gut microorganisms to treat cancer. Nat Med 29(8):1910-1911, 2023. e-Pub 2023. PMID: 37420098.
Chelvanambi M, Wargo JA. MAdCAM-1: a newly identified microbial 'gut check' for T cells. Trends Immunol 44(8):568-570, 2023. e-Pub 2023. PMID: 37451906.
Amit M, Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, Adewale A, Islam S, Mattson B, Ferrarotto R, Wong M, Davies M, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunarante P, Goepfert R, Khushalani N, Wang J, Watowich S, Calin G, Migden M, Vermeer P, D'Silva N, Yaniv D, Burks J, Gomez J, Dougherty P, Tsai K, Allison J, Sharma P, Wargo J, Myers J, Gross N. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
Baruch, EN, Nagarajan, P, Gleber-Netto, FO, Rao, X, Xie, T, Akhter, S, Adewale, A, Shajedul, I, Mattson, BJ, Ferrarotto, R, Wong, MK, Davies, MA, Jindal, S, Basu, S, Harwood, C, Leigh, I, Ajami, NJ, Futreal, A, Castillo, M, Gunaratne, PH, Goepfert, RP, Khushalani, N, Wang, J, Watowich, SS, Calin, GA, Migden, MR, Vermeer, PD, D'Silva, NJ, Yaniv, D, Burks, JK, Gomez, JA, Dougherty, PM, Tsai, KY, Allison, JP, Sharma, P, Wargo, J, Myers, JN, Gross, N, Amit, M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Research square, 2023. e-Pub 2023. PMID: 37503252.
Lucci A, Addanki S, Chiang YJ, Meas S, Sarli VN, Upshaw JR, Manchem M, Patel SP, Wargo JA, Gershenwald JE, Ross MI. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel) 15(14), 2023. e-Pub 2023. PMID: 37509290.
Seo YD, Wargo JA. From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Cell Rep Med 4(5):101039, 2023. e-Pub 2023. PMID: 37196631.
Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res 11(5):558-569, 2023. e-Pub 2023. PMID: 36820825.
Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, LaFleur MW, Johnson SB, Morad G, Park EM, Zhou Y, Watowich SS, Wargo JA, Freeman GJ, Kasper DL, Sharpe AH. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature 617(7960):377-385, 2023. e-Pub 2023. PMID: 37138075.
Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898-905, 2023. e-Pub 2023. PMID: 36997799.
Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of checkpoint blockade-associated toxicity. J Exp Med 220(3), 2023. e-Pub 2023. PMID: 36622383.
Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220(2), 2023. e-Pub 2023. PMID: 36367776.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4(+) T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer 4(2):222-239, 2023. e-Pub 2023. PMID: 36690875.
Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
Elnaggar JH, Huynh VO, Lin D, Hillman RT, Abana CO, El Alam MB, Tomasic KC, Karpinets TV, Kouzy R, Phan JL, Wargo J, Holliday EB, Das P, Mezzari MP, Ajami NJ, Lynn EJ, Minsky BD, Morris VK, Milbourne A, Messick CA, Klopp AH, Futreal PA, Taniguchi CM, Schmeler KM, Colbert LE. HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. Front Immunol 14:1051431, 2023. e-Pub 2023. PMID: 37063829.
Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer 10(12), 2022. e-Pub 2022. PMID: 36543374.
Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov 12(11):2626-2645, 2022. e-Pub 2022. PMID: 36098652.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med 28(11):2344-2352, 2022. e-Pub 2022. PMID: 36138151.
Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Pena J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. e-Pub 2022. PMID: 36179667.
Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 31:100813, 2022. e-Pub 2022. PMID: 35834946.
Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol 19(8):495-496, 2022. e-Pub 2022. PMID: 35449306.
Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Nat Commun 13(1):4000, 2022. e-Pub 2022. PMID: 35810190.
Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol 142(7):2046-2049.e3, 2022. e-Pub 2022. PMID: 34952092.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol 29(6):3694-3708, 2022. e-Pub 2022. PMID: 35089452.
Chelvanambi M, Wargo JA. Trust your gut when it comes to driving CARs. Med 3(5):281-283, 2022. e-Pub 2022. PMID: 35584646.
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
Cascone T, Chelvanambi M, Wargo JA. Immunotherapy response-associated Akkermansia: canary in a coal mine?. Trends Immunol 43(5):337-339, 2022. e-Pub 2022. PMID: 35397955.
Servetas SL, Daschner PJ, Guyard C, Thomas V, Affagard H, Sergaki C, Sokol H, Wargo JA, Wu GD, Sabot P. Evolution of FMT - From early clinical to standardized treatments. Biologicals 76:31-35, 2022. e-Pub 2022. PMID: 35086768.
Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res 10(3):303-313, 2022. e-Pub 2022. PMID: 35013003.
Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZ. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol 125(4):719-729, 2022. e-Pub 2022. PMID: 34904258.
Wargo JJ, Carr DR, Plaza JA, Verschraegen CF. Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition. J Natl Compr Canc Netw:1-3, 2022. e-Pub 2022. PMID: 35196645.
Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med 3(2):100500, 2022. e-Pub 2022. PMID: 35243413.
Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16(+) Cancers. Cancer Immunol Res 10(2):259-271, 2022. e-Pub 2022. PMID: 35045973.
Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
Chelvanambi M, Wargo JA. More fuel for the fire: Gut microbes and toxicity to immune agonist antibodies in cancer. Cell Rep Med 2(12):100482, 2021. e-Pub 2021. PMID: 35028621.
St Paul M, Saibil SD, Han S, Israni-Winger K, Lien SC, Laister RC, Sayad A, Penny S, Amaria RN, Haydu LE, Garcia-Batres CR, Kates M, Mulder DT, Robert-Tissot C, Gold MJ, Tran CW, Elford AR, Nguyen LT, Pugh TJ, Pinto DM, Wargo JA, Ohashi PS. Coenzyme A fuels T cell anti-tumor immunity. Cell Metab 33(12):2415-2427.e6, 2021. e-Pub 2021. PMID: 34879240.
Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771465.
Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lopes A, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184(21):5338-5356.e21, 2021. e-Pub 2021. PMID: 34624222.
Spandau DF, Chen R, Wargo JJ, Rohan CA, Southern D, Zhang A, Loesch M, Weyerbacher J, Tholpady SS, Lewis DA, Kuhar M, Tsai KY, Castellanos AJ, Kemp MG, Markey M, Cates E, Williams AR, Knisely C, Bashir S, Gabbard R, Hoopes R, Travers JB. Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia. J Clin Invest 131(19), 2021. e-Pub 2021. PMID: 34428179.
Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
Cascone T, Weissferdt A, Godoy MCB, William WN Jr, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM Jr, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
Ambardekar AP, Walker KK, McKenzie-Brown AM, Brennan K, Jackson C, Edgar L, Ellinas H, Long TR, Trombetta CE, Laskey MG, Wargo BW, Dainer RJ, Draconi CS, Mitchell JD. The Anesthesiology Milestones 2.0: An Improved Competency-Based Assessment for Residency Training. Anesth Analg 133(2):353-361, 2021. e-Pub 2021. PMID: 33764340.
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, Saponara M, Orsolini G, Zagami P, Nicolo E, De Marinis F, Tortora G, Bria E, Minucci S, Joffe H, Veronesi P, Wargo J, Rosenthal R, Swanton C, Mantovani A, Gelber RD, Viale G, Goldhirsch A, Giaccone G. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res 27(15):4311-4324, 2021. e-Pub 2021. PMID: 34016641.
Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun 12(1):4031, 2021. e-Pub 2021. PMID: 34188042.
Oliveira G, Wargo JM. Collison, Connection, and Conflict? Writing (Righting) Community Amid COVID-19. J Adolesc Adult Lit 64(6):708-711, 2021. e-Pub 2021. PMID: 34149277.
Wargo AR, Kurath G, Scott RJ, Kerr B. Virus shedding kinetics and unconventional virulence tradeoffs. PLoS Pathog 17(5):e1009528, 2021. e-Pub 2021. PMID: 33970967.
Wargo JJ, Plaza JA, Carr D. Sebaceous neoplasia leading to the diagnosis of Muir-Torre syndrome in an African American man. JAAD Case Rep 11:72-73, 2021. e-Pub 2021. PMID: 33937470.
Sweeney KJ, Tetzlaff MT, Vega F, Gillenwater A, Zuo Z, Gross N, Nagarajan P, Wargo J, Nelson K, Prieto VG, Torres-Cabala CA, Curry JL. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. J Cutan Pathol 48(5):674-679, 2021. e-Pub 2021. PMID: 33399228.
Olsen TG, Shrit MA, Feeser TA, Wargo JJ. COVID Purpura (Toes) Case Series: A Chilblains-Like Vasculopathy. Am J Dermatopathol 43(4):e47-e50, 2021. e-Pub 2021. PMID: 33156022.
Wargo JJ, Carr D, Chung C. Intraepidermal apocrine differentiation in an infantile nevus sebaceus. J Cutan Pathol 48(4):595-597, 2021. e-Pub 2021. PMID: 33010042.
Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, Bussi Y, Rotkopf R, Levy R, Benedek G, Trabish S, Dadosh T, Levin-Zaidman S, Geller LT, Wang K, Greenberg P, Yagel G, Peri A, Fuks G, Bhardwaj N, Reuben A, Hermida L, Johnson SB, Galloway-Pena JR, Shropshire WC, Bernatchez C, Haymaker C, Arora R, Roitman L, Eilam R, Weinberger A, Lotan-Pompan M, Lotem M, Admon A, Levin Y, Lawley TD, Adams DJ, Levesque MP, Besser MJ, Schachter J, Golani O, Segal E, Geva-Zatorsky N, Ruppin E, Kvistborg P, Peterson SN, Wargo JA, Straussman R, Samuels Y. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592(7852):138-143, 2021. e-Pub 2021. PMID: 33731925.
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE, Klopp AH. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol 4(1):237, 2021. e-Pub 2021. PMID: 33619320.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371(6529):602-609, 2021. e-Pub 2021. PMID: 33303685.
Wargo JJ, Weir NM, Shamma HN. Coronavirus (COVID-19) Infection-Induced Chilblains: A Brisk Perieccrine Inflammatory Response. Am J Dermatopathol 43(2):144-145, 2021. e-Pub 2021. PMID: 32618705.
Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 27(2):301-309, 2021. e-Pub 2021. PMID: 33558722.
Bartok O, Pataskar A, Nagel R, Laos M, Goldfarb E, Hayoun D, Levy R, Korner PR, Kreuger IZM, Champagne J, Zaal EA, Bleijerveld OB, Huang X, Kenski J, Wargo J, Brandis A, Levin Y, Mizrahi O, Alon M, Lebon S, Yang W, Nielsen MM, Stern-Ginossar N, Altelaar M, Berkers CR, Geiger T, Peeper DS, Olweus J, Samuels Y, Agami R. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590(7845):332-337, 2021. e-Pub 2021. PMID: 33328638.
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun 12(1):346, 2021. e-Pub 2021. PMID: 33436641.
Everson JL, Jones DR, Taylor AK, Rutan BJ, Leeds TD, Langwig KE, Wargo AR, Wiens GD. Aquaculture Reuse Water, Genetic Line, and Vaccination Affect Rainbow Trout (Oncorhynchus mykiss) Disease Susceptibility and Infection Dynamics. Front Immunol 12:721048, 2021. e-Pub 2021. PMID: 34630394.
El Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude JABI, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One 16(3):e0247905, 2021. e-Pub 2021. PMID: 33662003.
White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology 10(1):1992880, 2021. e-Pub 2021. PMID: 34777916.
Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31(11):1569-1579, 2020. e-Pub 2020. PMID: 32739408.
Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol 140(11):2146-2156.e4, 2020. e-Pub 2020. PMID: 32304704.
Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA, Ivan C, Ju Z, Nwajei F, Wang J, Davies MA, Davis RE, Wargo JA, Bhattacharya PK, Hong DS, Curran MA. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res 8(11):1365-1380, 2020. e-Pub 2020. PMID: 32917656.
Khatib J, Wargo JJ, Krishnamurthy S, Travers JB. Hemorrhagic Bullous Lichen Sclerosus: A Case Report. Am J Case Rep 21:e919353, 2020. e-Pub 2020. PMID: 33024070.
White MG, Wargo JA. Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell 79(6):878-880, 2020. e-Pub 2020. PMID: 32946762.
Wargo JA. Modulating gut microbes. Science 369(6509):1302-1303, 2020. e-Pub 2020. PMID: 32913089.
Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L. Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. Nat Rev Immunol 20(9):522-528, 2020. e-Pub 2020. PMID: 32661409.
Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A, Jones MA, Reyzer M, Bates BM, Spraggins JM, Patterson NH, McLean JA, Rai K, Tacchetti C, Tucci S, Wargo JA, Rodighiero S, Clise-Dwyer K, Sherrod SD, Kim M, Navin NE, Caprioli RM, Greenberg PD, Draetta G, Nezi L. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med 217(8), 2020. e-Pub 2020. PMID: 32491160.
Galloway-Pena JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis 71(1):63-71, 2020. e-Pub 2020. PMID: 31436833.
Fang S, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis 41(4):452-457, 2020. e-Pub 2020. PMID: 31630191.
Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368(6494):973-980, 2020. e-Pub 2020. PMID: 32467386.
Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):1429-1441, 2020. e-Pub 2020. PMID: 31990608.
Helmink BA, Roland CL, Kiernan CM, Wargo JA. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Ann Surg Oncol 27(5):1533-1545, 2020. e-Pub 2020. PMID: 31965370.
Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res 26(6):1258-1266, 2020. e-Pub 2020. PMID: 31900276.
Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol 33(3):496-513, 2020. e-Pub 2020. PMID: 31383963.
Chen YT, Barcelona JM, Cance JD, Calvert HG, Barnes SP, Wargo J, Castelli DM. Development of the Fitness Education Index: A Scale of Organizational Level Capacity. Res Q Exerc Sport 91(1):172-178, 2020. e-Pub 2020. PMID: 31617835.
Ajami NJ, Wargo JA. AI finds microbial signatures in tumours and blood across cancer types. Nature 579(7800):502-503, 2020. e-Pub 2020. PMID: 32161344.
Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun 11(1):853, 2020. e-Pub 2020. PMID: 32051401.
Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys 106(2):349-357, 2020. e-Pub 2020. PMID: 31678224.
Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautes-Fridman C, Tawbi HA, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556-560, 2020. e-Pub 2020. PMID: 31942077.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Lovgren K, Warren S, Jirstrom K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, Jonsson G. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561-565, 2020. e-Pub 2020. PMID: 31942071.
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautes-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
Chen R, Wargo JJ, Williams A, Cates E, Spandau DF, Knisely C, Travers JB. Single Ablative Fractional Resurfacing Laser Treatment For Forearm Actinic Keratoses: 6-Month Follow-Up Data From An Intrapatient Comparison Between Treated and Untreated Sites. Lasers Surg Med 52(1):84-87, 2020. e-Pub 2020. PMID: 31736123.
Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A 116(45):22699-22709, 2019. e-Pub 2019. PMID: 31636208.
Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol 139(11):2352-2358.e3, 2019. e-Pub 2019. PMID: 31176707.
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vetizou M, Daillere R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res 29(10):846-861, 2019. e-Pub 2019. PMID: 31481761.
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hammond SA, Tan M, Qi J, Wong P, Merghoub T, Wolchok J, Hacohen N, Janik JE, Mkrtichyan M, Gupta S, Khleif SN. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat Immunol 20(9):1231-1243, 2019. e-Pub 2019. PMID: 31358999.
Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14(+) and CD16(+) monocytes driving an innate immune response. J Cutan Pathol 46(9):627-636, 2019. e-Pub 2019. PMID: 30883858.
Lucas IR, Harris C, Lee S, Wargo J, Barnes SP, Kauh TJ, Iachan R. Teacher Physical Education Practices and Student Outcomes in a Sample of Middle Schools Participating in the Presidential Youth Fitness Program. Prev Chronic Dis 16:E104, 2019. e-Pub 2019. PMID: 31400098.
Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell 178(4):795-806.e12, 2019. e-Pub 2019. PMID: 31398337.
Helmink B, Wargo JA. Neoadjuvant therapy for melanoma: is it ready for prime time?. Lancet Oncol 20(7):892-894, 2019. e-Pub 2019. PMID: 31171445.
Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res 25(11):3455-3467, 2019. e-Pub 2019. PMID: 30808776.
Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res 7(6):1025-1035, 2019. e-Pub 2019. PMID: 31043414.
Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers (Basel) 11(6), 2019. e-Pub 2019. PMID: 31146499.
Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high) /AXL(low) melanoma. Pigment Cell Melanoma Res 32(2):280-291, 2019. e-Pub 2019. PMID: 30277012.
Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma. Pigment Cell Melanoma Res 32(2):280-291, 2019. e-Pub 2019.
Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res 25(4):1233-1238, 2019. e-Pub 2019. PMID: 30054281.
Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res 25(4):1233-1238, 2019. e-Pub 2019.
Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT. Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia. Br J Dermatol 180(2):404-408, 2019. e-Pub 2019. PMID: 29897634.
Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT. Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov 9(1):64-81, 2019. e-Pub 2019. PMID: 30279173.
Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo JA, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019.
Kaur A, Ecker BL, Douglass SM, CHrd K, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov 9(1):64-81, 2019. e-Pub 2019.
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018.
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 175(4):998-1013.e20, 2018. e-Pub 2018. PMID: 30388456.
Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018.
Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov 8(11):1366-1375, 2018. e-Pub 2018. PMID: 30209080.
Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov 8(11):1366-1375, 2018. e-Pub 2018.
Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets TV, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth C, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn CS, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MKK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018.
Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018.
Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29(8):1861-1868, 2018. e-Pub 2018. PMID: 29945191.
Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. Ann Surg Oncol 25(7):1814-1827, 2018. e-Pub 2018.
Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. PMID: 29496759.
Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol 25(7):1814-1827, 2018. e-Pub 2018. PMID: 29500764.
Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology 26(7(9)):e1475874, 2018. e-Pub 2018.
Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol 45(7):545-549, 2018. e-Pub 2018. PMID: 29672900.
Helmink BA, Gaudreau PO, Wargo JA. Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity 48(6):1077-1080, 2018. e-Pub 2018. PMID: 29924973.
Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A Preexisting Rare PIK3CA(E545K) Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8(5):556-567, 2018. e-Pub 2018. PMID: 29496665.
McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19(3):310-322, 2018. e-Pub 2018. PMID: 29449192.
Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6(1):14, 2018. e-Pub 2018. PMID: 29433571.
Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology 7(5):e1423172, 2018. e-Pub 2018.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018.
Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology 7(9):e1475874, 2018. e-Pub 2018. PMID: 30228943.
Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2018. e-Pub 2018. PMID: 29308306.
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology 7(5):e1423172, 2018. e-Pub 2018. PMID: 29721378.
Karpinets TV, Gopalakrishnan V, Wargo J, Futreal AP, Schadt CW, Zhang J. Linking Associations of Rare Low-Abundance Species to Their Environments by Association Networks. Front Microbiol 9:297, 2018. e-Pub 2018. PMID: 29563898.
Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med 15(1):236, 2017. e-Pub 2017. PMID: 29145885.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21(7):1953-1967, 2017. e-Pub 2017. PMID: 29141225.
Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21(7):1936-1952, 2017. e-Pub 2017. PMID: 29141224.
Andrews MC, Wargo JA. Cancer Evolution during Immunotherapy. Cell 171(4):740-742, 2017. e-Pub 2017. PMID: 29100071.
Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2017. e-Pub 2017.
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhofer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8(1):607, 2017. e-Pub 2017. PMID: 28928360.
Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156-1160, 2017. e-Pub 2017. PMID: 28912244.
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. PMID: 28803728.
Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res 23(16):4680-4692, 2017. e-Pub 2017. PMID: 28446504.
Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med 9(8):1011-1029, 2017. e-Pub 2017. PMID: 28606996.
Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7(8):832-851, 2017. e-Pub 2017. PMID: 28455392.
Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med 214(6):1691-1710, 2017. e-Pub 2017. PMID: 28450382.
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo JA, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med(5):551-555, 2017. e-Pub 2017.
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2017. PMID: 27911979.
Gee MS, Ghazani AA, Haq R, Wargo JA, Sebas M, Sullivan RJ, Lee H, Weissleder R. Point of care assessment of melanoma tumor signaling and metastatic burden from muNMR analysis of tumor fine needle aspirates and peripheral blood. Nanomedicine 13(3):821-828, 2017. e-Pub 2017. PMID: 27993725.
Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017.
Wargo JJ, Adams M, Trevino J. Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis. BMJ Case Rep 2017, 2017. e-Pub 2017. PMID: 28137903.
Cogdill AP, Prieto PA, Reuben A, Wargo JA. Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. Clin Cancer Res 23(2):327-329, 2017. e-Pub 2017. PMID: 27836861.
Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6(12):e1361097, 2017. e-Pub 2017. PMID: 29209563.
Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6(6):e1321187, 2017. e-Pub 2017. PMID: 28680759.
Villani V, Mahadevan KK, Ligorio M, Fernandez-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 23(Suppl 5):609-617, 2016. e-Pub 2016. PMID: 27020585.
Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res 22(22):5553-5563, 2016. e-Pub 2016. PMID: 27166398.
Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med 14(1):313, 2016. e-Pub 2016. PMID: 27846884.
Feldmeyer L, Hudgens CW, Lyons GR, Nagarajan P, Aung PP, Curry JL, Torres Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res 22(22):5553-5563, 2016. e-Pub 2016.
Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther 15(10):2442-2454, 2016. e-Pub 2016. PMID: 27458138.
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 537(7619):254, 2016. e-Pub 2016. PMID: 27383789.
Wargo JJ, Berg A, Gudjonsson JE. Ongoing Pleuritic Chest Pain and a Guinea Pig: Missed Pulmonary Embolism and Majocchi's Granuloma. Am J Med 129(9):e165-7, 2016. e-Pub 2016. PMID: 27103050.
Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jane-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016.
Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
Galloway-Pena JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016.
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016. PMID: 27087480.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016.
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, Wood T, Luo F, Stevenson R, Polimanti R, Gelernter J, Lin X, Lim IY, Wu Y, Teh AL, Chen L, Aris IM, Soh SE, Tint MT, MacIsaac JL, Yap F, Kwek K, Saw SM, Kobor MS, Meaney MJ, Godfrey KM, Chong YS, Holbrook JD, Lee YS, Gluckman PD, Karnani N, Kapoor A, Lee D, Chakravarti A, Maercker C, Graf F, Boutros M, Stamoulis G, Santoni F, Makrythanasis P, Letourneau A, Guipponi M, Panousis N, Garieri M, Ribaux P, Falconnet E, Borel C, Antonarakis SE, Kumar S, Curran J, Blangero J, Chatterjee S, Kapoor A, Akiyama J, Auer D, Berrios C, Pennacchio L, Chakravarti A, Donti TR, Cappuccio G, Miller M, Atwal P, Kennedy A, Cardon A, Bacino C, Emrick L, Hertecant J, Baumer F, Porter B, Bainbridge M, Bonnen P, Graham B, Sutton R, Sun Q, Elsea S, Hu Z, Wang P, Zhu Y, Zhao J, Xiong M, Bennett DA, Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D'Ippolito E, Baroni S, Kaczkowski B, Tanaka Y, Kawaji H, Sandelin A, Andersson R, Itoh M, Lassmann T, Hayashizaki Y, Carninci P, Forrest ARR, Semple CA, Rosenthal EA, Shirts B, Amendola L, Gallego C, Horike-Pyne M, Burt A, Robertson P, Beyers P, Nefcy C, Veenstra D, Hisama F, Bennett R, Dorschner M, Nickerson D, Smith J, Patterson K, Crosslin D, Nassir R, Zubair N, Harrison T, Peters U, Jarvik G, Menghi F, Inaki K, Woo X, Kumar P, Grzeda K, Malhotra A, Kim H, Ucar D, Shreckengast P, Karuturi K, Keck J, Chuang J, Liu ET, Ji B, Tyler A, Ananda G, Carter G, Nikbakht H, Montagne M, Zeinieh M, Harutyunyan A, Mcconechy M, Jabado N, Lavigne P, Majewski J, Goldstein JB, Overman M, Varadhachary G, Shroff R, Wolff R, Javle M, Futreal A, Fogelman D, Bravo L, Fajardo W, Gomez H, Castaneda C, Rolfo C, Pinto JA, Akdemir KC, Chin L, Futreal A, Patterson S, Statz C, Mockus S, Nikolaev SN, Bonilla XI, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy V, Sharpe H, McKee T, Letourneau A, Ribaux P, Popadin K, Basset-Seguin N, Chaabene RB, Santoni F, Andrianova M, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage F, Antonarakis S, Likhitrattanapisal S, Lincoln S, Kurian A, Desmond A, Yang S, Kobayashi Y, Ford J, Ellisen L, Peters TL, Alvarez KR, Hollingsworth EF, Lopez-Terrada DH, Hastie A, Dzakula Z, Pang AW, Lam ET, Anantharaman T, Saghbini M, Cao H, Gonzaga-Jauregui C, Ma L, King A, Rosenzweig EB, Krishnan U, Reid JG, Overton JD, Dewey F, Chung WK, Small K, DeLuca A, Cremers F, Lewis RA, Puech V, Bakall B, Silva-Garcia R, Rohrschneider K, Leys M, Shaya FS, Stone E, Sobreira NL, Schiettecatte F, Ling H, Pugh E, Witmer D, Hetrick K, Zhang P, Doheny K, Valle D, Hamosh A, Jhangiani SN, Akdemir ZC, Bainbridge MN, Charng W, Wiszniewski W, Gambin T, Karaca E, Bayram Y, Eldomery MK, Posey J, Doddapaneni H, Hu J, Sutton VR, Muzny DM, Boerwinkle EA, Valle D, Lupski JR, Gibbs RA, Shekar S, Salerno W, English A, Mangubat A, Bruestle J, Thorogood A, Knoppers BM, Takahashi H, Nitta KR, Kozhuharova A, Suzuki AM, Sharma H, Cotella D, Santoro C, Zucchelli S, Gustincich S, Carninci P, Mulvihill JJ, Baynam G, Gahl W, Groft SC, Kosaki K, Lasko P, Melegh B, Taruscio D, Ghosh R, Plon S, Scherer S, Qin X, Sanghvi R, Walker K, Chiang T, Muzny D, Wang L, Black J, Boerwinkle E, Weinshilboum R, Gibbs R, Karpinets T, Calderone T, Wani K, Yu X, Creasy C, Haymaker C, Forget M, Nanda V, Roszik J, Wargo J, Haydu L, Song X, Lazar A, Gershenwald J, Davies M, Bernatchez C, Zhang J, Futreal A, Woodman S, Chesler EJ, Reynolds T, Bubier JA, Phillips C, Langston MA, Baker EJ, Xiong M, Ma L, Lin N, Amos C, Lin N, Wang P, Zhu Y, Zhao J, Calhoun V, Xiong M, Dobretsberger O, Egger M, Leimgruber F, Sadedin S, Oshlack A, Antonio VAA, Ono N, Ahmed Z, Bolisetty M, Zeeshan S, Anguiano E, Ucar D, Sarkar A, Nandineni MR, Zeng C, Shao J, Cao H, Hastie A, Pang AW, Lam ET, Liang T, Pham K, Saghbini M, Dzakula Z, Chee-Wei Y, Dongsheng L, Lai-Ping W, Lian D, Hee ROT, Yunus Y, Aghakhanian F, Mokhtar SS, Lok-Yung CV, Bhak J, Phipps M, Shuhua X, Yik-Ying T, Kumar V, Boon-Peng H, Campbell I, Young MA, James P, Rain M, Mohammad G, Kukreti R, Pasha Q, Akilzhanova AR, Guelly C, Abilova Z, Rakhimova S, Akhmetova A, Kairov U, Trajanoski S, Zhumadilov Z, Bekbossynova M, Schumacher C, Sandhu S, Harkins T, Makarov V, Doddapaneni H, Glenn R, Momin Z, Dilrukshi B, Chao H, Meng Q, Gudenkauf B, Kshitij R, Jayaseelan J, Nessner C, Lee S, Blankenberg K, Lewis L, Hu J, Han Y, Dinh H, Jireh S, Walker K, Boerwinkle E, Muzny D, Gibbs R, Hu J, Walker K, Buhay C, Liu X, Wang Q, Sanghvi R, Doddapaneni H, Ding Y, Veeraraghavan N, Yang Y, Boerwinkle E, Beaudet AL, Eng CM, Muzny DM, Gibbs RA, Worley KCC, Liu Y, Hughes DST, Murali SC, Harris RA, English AC, Qin X, Hampton OA, Larsen P, Beck C, Han Y, Wang M, Doddapaneni H, Kovar CL, Salerno WJ, Yoder A, Richards S, Rogers J, Lupski JR, Muzny DM, Gibbs RA, Meng Q, Bainbridge M, Wang M, Doddapaneni H, Han Y, Muzny D, Gibbs R, Harris RA, Raveenedran M, Xue C, Dahdouli M, Cox L, Fan G, Ferguson B, Hovarth J, Johnson Z, Kanthaswamy S, Kubisch M, Platt M, Smith D, Vallender E, Wiseman R, Liu X, Below J, Muzny D, Gibbs R, Yu F, Rogers J, Lin J, Zhang Y, Ouyang Z, Moore A, Wang Z, Hofmann J, Purdue M, Stolzenberg-Solomon R, Weinstein S, Albanes D, Liu CS, Cheng WL, Lin TT, Lan Q, Rothman N, Berndt S, Chen ES, Bahrami H, Khoshzaban A, Keshal SH, Bahrami H, Khoshzaban A, Keshal SH, Alharbi KKR, Zhalbinova M, Akilzhanova A, Rakhimova S, Bekbosynova M, Myrzakhmetova S, Matar M, Mili N, Molinari R, Ma Y, Guerrier S, Elhawary N, Tayeb M, Bogari N, Qotb N, McClymont SA, Hook PW, Goff LA, McCallion A, Kong Y, Charette JR, Hicks WL, Naggert JK, Zhao L, Nishina PM, Edrees BM, Athar M, Al-Allaf FA, Taher MM, Khan W, Bouazzaoui A, Harbi NA, Safar R, Al-Edressi H, Anazi A, Altayeb N, Ahmed MA, Alansary K, Abduljaleel Z, Kratz A, Beguin P, Poulain S, Kaneko M, Takahiko C, Matsunaga A, Kato S, Suzuki AM, Bertin N, Lassmann T, Vigot R, Carninci P, Plessy C, Launey T, Graur D, Lee D, Kapoor A, Chakravarti A, Friis-Nielsen J, Izarzugaza JM, Brunak S, Chakraborty A, Basak J, Mukhopadhyay A, Soibam BS, Das D, Biswas N, Das S, Sarkar S, Maitra A, Panda C, Majumder P, Morsy H, Gaballah A, Samir M, Shamseya M, Mahrous H, Ghazal A, Arafat W, Hashish M, Gruber JJ, Jaeger N, Snyder M, Patel K, Bowman S, Davis T, Kraushaar D, Emerman A, Russello S, Henig N, Hendrickson C, Zhang K, Rodriguez-Dorantes M, Cruz-Hernandez CD, Garcia-Tobilla CDP, Solorzano-Rosales S, Jager N, Chen J, Haile R, Hitchins M, Brooks JD, Snyder M, Jimenez-Morales S, Ramirez M, Nunez J, Bekker V, Leal Y, Jimenez E, Medina A, Hidalgo A, Mejia J, Halytskiy V, Naggert J, Collin GB, DeMauro K, Hanusek R, Nishina PM, Belhassa K, Belhassan K, Bouguenouch L, Samri I, Sayel H, moufid FZ, El Bouchikhi I, Trhanint S, Hamdaoui H, Elotmani I, Khtiri I, Kettani O, Quibibo L, Ahagoud M, Abbassi M, Ouldim K, Marusin AV, Kornetov AN, Swarovskaya M, Vagaiceva K, Stepanov V, De La Paz EMC, Sy R, Nevado J, Reganit P, Santos L, Magno JD, Punzalan FE, Ona D, Llanes E, Santos-Cortes RL, Tiongco R, Aherrera J, Abrahan L, Pagauitan-Alan P, Morelli KH, Domire JS, Pyne N, Harper S, Burgess R, Zhalbinova M, Akilzhanova A, Rakhimova S, Bekbosynova M, Myrzakhmetova S, Gari MA, Dallol A, Alsehli H, Gari A, Gari M, Abuzenadah A, Thomas M, Sukhai M, Garg S, Misyura M, Zhang T, Schuh A, Stockley T, Kamel-Reid S, Sherry S, Xiao C, Slotta D, Rodarmer K, Feolo M, Kimelman M, Godynskiy G, O'Sullivan C, Yaschenko E, Xiao C, Yaschenko E, Sherry S, Rangel-Escareno C, Rueda-Zarate H, Tayubi IA, Mohammed R, Ahmed I, Ahmed T, Seth S, Amin S, Song X, Mao X, Sun H, Verhaak RG, Futreal A, Zhang J, Whiite SJ, Chiang T, English A, Farek J, Kahn Z, Salerno W, Veeraraghavan N, Boerwinkle E, Gibbs R, Kasukawa T, Lizio M, Harshbarger J, Hisashi S, Severin J, Imad A, Sahin S, Freeman TC, Baillie K, Sandelin A, Carninci P, Forrest ARR, Kawaji H, Salerno W, English A, Shekar SN, Mangubat A, Bruestle J, Boerwinkle E, Gibbs RA, Salem AH, Ali M, Ibrahim A, Ibrahim M, Barrera HA, Garza L, Torres JA, Barajas V, Ulloa-Aguirre A, Kershenobich D, Mortaji S, Guizar P, Loera E, Moreno K, De Leon A, Monsivais D, Gomez J, Cardiel R, Fernandez-Lopez JC, Bonifaz-Pena V, Rangel-Escareno C, Hidalgo-Miranda A, Contreras AV, Polfus L, Wang X, Philip V, Carter G, Abuzenadah AA, Gari M, Turki R, Dallol A, Uyar A, Kaygun A, Zaman S, Marquez E, George J, Ucar D, Hendrickson CL, Emerman A, Kraushaar D, Bowman S, Henig N, Davis T, Russello S, Patel K, Starr DB, Baird M, Kirkpatrick B, Sheets K, Nitsche R, Prieto-Lafuente L, Landrum M, Lee J, Rubinstein W, Maglott D, Thavanati PKR, de Dios AE, Hernandez REN, Aldrate MEA, Mejia MRR, Kanala KRR, Abduljaleel Z, Khan W, Al-Allaf FA, Athar M, Taher MM, Shahzad N, Bouazzaoui A, Huber E, Dan A, Al-Allaf FA, Herr W, Sprotte G, Kostler J, Hiergeist A, Gessner A, Andreesen R, Holler E, Al-Allaf F, Alashwal A, Abduljaleel Z, Taher M, Bouazzaoui A, Abalkhail H, Al-Allaf A, Bamardadh R, Athar M, Filiptsova O, Kobets M, Kobets Y, Burlaka I, Timoshyna I, Filiptsova O, Kobets MN, Kobets Y, Burlaka I, Timoshyna I, Filiptsova O, Kobets MN, Kobets Y, Burlaka I, Timoshyna I, Al-allaf FA, Mohiuddin MT, Zainularifeen A, Mohammed A, Abalkhail H, Owaidah T, Bouazzaoui A. Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016. Hum Genomics 10 Suppl 1(Suppl 1):12, 2016. e-Pub 2016. PMID: 27294413.
Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834-56, 2016. e-Pub 2016. PMID: 27043285.
Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo JA, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016.
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532(7598):250-4, 2016. e-Pub 2016. PMID: 27042933.
Wargo JJ, Emmer BT. Systemic Inflammation Gone Awry: PASH Syndrome and Temporomandibular Joint Ankylosis. Am J Med 129(4):e1-3, 2016. e-Pub 2016. PMID: 26772651.
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell 29(3):270-284, 2016. e-Pub 2016. PMID: 26977879.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35(10):1225-35, 2016. e-Pub 2016. PMID: 26073081.
Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35(10):1225-35, 2016. e-Pub 2016.
Hu Z, Xia J, Fan W, Wargo J, Yang YG. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget 7(6):6448-59, 2016. e-Pub 2016. PMID: 26824989.
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KSM. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol 135(12):3115-3124, 2015. e-Pub 2015. PMID: 26302068.
Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA. Working with Human Tissues for Translational Cancer Research. J Vis Exp(105), 2015. e-Pub 2015. PMID: 26649748.
Reuben A, Austin-Breneman J, Wargo JA, Cooper ZA. Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Ann Transl Med 3(18):272, 2015. e-Pub 2015. PMID: 26605318.
Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res 21(14):3102-4, 2015. e-Pub 2015. PMID: 26025561.
Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jonsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol 135(7):1863-1872, 2015. e-Pub 2015. PMID: 25789707.
Wargo JJ, Kim AH, Hart A, Berg A. It Took a Village: Good's Syndrome. Am J Med 128(7):699-701, 2015. e-Pub 2015. PMID: 25796418.
Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep 11(9):1458-73, 2015. e-Pub 2015. PMID: 26027934.
Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol 42(5):308-17, 2015. e-Pub 2015. PMID: 25754356.
Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 125(4):1459-70, 2015. e-Pub 2015. PMID: 25705882.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Munoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47(3):250-6, 2015. e-Pub 2015. PMID: 25665005.
Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov 5(3):274-87, 2015. e-Pub 2015. PMID: 25542448.
Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle 14(12):1765-6, 2015. e-Pub 2015. PMID: 26036142.
Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA. Working with human tissues for translational cancer research. J Vis Exp(105), 2015. e-Pub 2015.
Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Pena J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One 10(10):e0140310, 2015. e-Pub 2015. PMID: 26461489.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal 7(357):ra121, 2014. e-Pub 2014. PMID: 25538079.
Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma. Cancer Res 74(23):7037-47, 2014. e-Pub 2014. PMID: 25297634.
Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther 13(12):3210-8, 2014. e-Pub 2014. PMID: 25319388.
Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 193(9):4722-31, 2014. e-Pub 2014. PMID: 25252955.
Reuben A, Amaria RN, Cooper ZA, Wargo JA. RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. J Pigment Disord 1(5), 2014. e-Pub 2014. PMID: 29250602.
Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov 4(10):1214-1229, 2014. e-Pub 2014. PMID: 25256614.
Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology 3(9):e954956, 2014. e-Pub 2014. PMID: 25941608.
Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer Immunol Res 2(8):714-9, 2014. e-Pub 2014. PMID: 25092813.
Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid 24(8):1241-50, 2014. e-Pub 2014. PMID: 24811699.
Konstantinidis IT, Kambadakone A, Catalano OA, Sahani DV, Deshpande V, Forcione DG, Wargo JA, Fernandez-Del Castillo C, Lillemoe KD, Warshaw AL, Ferrone CR. Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. World J Gastrointest Surg 6(7):136-41, 2014. e-Pub 2014. PMID: 25068011.
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 4(7):816-27, 2014. e-Pub 2014. PMID: 24771846.
Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2(7):643-54, 2014. e-Pub 2014. PMID: 24903021.
Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRalpha up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5(7):1926-41, 2014. e-Pub 2014. PMID: 24732172.
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4(1):61-8, 2014. e-Pub 2014. PMID: 24265154.
Fong ZV, Ferrone CR, Thayer SP, Wargo JA, Sahora K, Seefeld KJ, Warshaw AL, Lillemoe KD, Hutter MM, Fernandez-Del Castillo C. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg 18(1):137-44; discussion 144-5, 2014. e-Pub 2014. PMID: 24002770.
Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 9(7):e101286, 2014. e-Pub 2014. PMID: 24983357.
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504(7478):138-42, 2013. e-Pub 2013. PMID: 24185007.
Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery 154(6):1456-62; discussion 1462, 2013. e-Pub 2013. PMID: 24238058.
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3(12):1378-93, 2013. e-Pub 2013. PMID: 24104062.
Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2(10):e26615, 2013. e-Pub 2013. PMID: 24251082.
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 5(196):196ra98, 2013. e-Pub 2013. PMID: 23903755.
Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med 369(2):173-83, 2013. e-Pub 2013. PMID: 23841733.
Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2(5):e24320, 2013. e-Pub 2013. PMID: 23762807.
Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?. Ann Surg 257(4):731-6, 2013. e-Pub 2013. PMID: 22968073.
Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23(3):302-15, 2013. e-Pub 2013. PMID: 23477830.
Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110(11):4321-6, 2013. e-Pub 2013. PMID: 23447565.
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizee G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225-31, 2013. e-Pub 2013. PMID: 23307859.
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3(3):338-49, 2013. e-Pub 2013. PMID: 23171796.
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 19(3):598-609, 2013. e-Pub 2013. PMID: 23095323.
Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernandez-del Castillo C, Warshaw AL, Thayer SP. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 17(2):257-66, 2013. e-Pub 2013. PMID: 23229885.
Clifton MS, Wargo JP, Weathers WS, Colon M, Bennett DH, Tulve NS. Quantitative analysis of organophosphate and pyrethroid insecticides, pyrethroid transformation products, polybrominated diphenyl ethers and bisphenol A in residential surface wipe samples. J Chromatogr A 1273:1-11, 2013. e-Pub 2013. PMID: 23265991.
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizee G, Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 19(2):393-403, 2013. e-Pub 2013. PMID: 23204132.
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 18(5):543-8, 2013. e-Pub 2013. PMID: 23657686.
Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-53, 2012. e-Pub 2012. PMID: 23123854.
Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizee G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18(10):1503-10, 2012. e-Pub 2012. PMID: 22983396.
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43-9, 2012. e-Pub 2012. PMID: 22763261.
Fernandez-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, Lillemoe KD, Warshaw AL. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 152(3 Suppl 1):S56-63, 2012. e-Pub 2012. PMID: 22770961.
Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernandez-del Castillo C. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 152(3 Suppl 1):S4-12, 2012. e-Pub 2012. PMID: 22770958.
Cogdill AP, Frederick DT, Cooper ZA, Garber HR, Ferrone CR, Fiedler A, Rosenberg L, Thayer SP, Warshaw AL, Wargo JA. Targeting the MAGE A3 antigen in pancreatic cancer. Surgery 152(3 Suppl 1):S13-8, 2012. e-Pub 2012. PMID: 22770803.
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500-4, 2012. e-Pub 2012. PMID: 22763439.
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell 150(2):251-63, 2012. e-Pub 2012. PMID: 22817889.
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502-6, 2012. e-Pub 2012. PMID: 22622578.
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2(3):227-35, 2012. e-Pub 2012. PMID: 22448344.
Cecchini S, Correa-Gallego C, Desphande V, Ligorio M, Dursun A, Wargo J, Fernandez-del Castillo C, Warshaw AL, Ferrone CR. Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenocarcinoma. J Gastrointest Surg 16(1):113-20; discussion 120, 2012. e-Pub 2012. PMID: 22005894.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387-90, 2011. e-Pub 2011. PMID: 22113612.
Ferrone CR, Konstantinidis IT, Sahani DV, Wargo JA, Fernandez-del Castillo C, Warshaw AL. Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. Ann Surg 253(6):1136-9, 2011. e-Pub 2011. PMID: 21394008.
Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernandez-del Castillo C. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg 146(5):534-8, 2011. e-Pub 2011. PMID: 21576607.
Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 186(2):685-96, 2011. e-Pub 2011. PMID: 21149604.
Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 186(2):685-96, 2011. e-Pub 2011.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-72, 2010. e-Pub 2010. PMID: 21107320.
Konstantinidis IT, Dursun A, Zheng H, Wargo JA, Thayer SP, Fernandez-del Castillo C, Warshaw AL, Ferrone CR. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg 211(6):749-53, 2010. e-Pub 2010. PMID: 21109158.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-72, 2010. e-Pub 2010.
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213-9, 2010. e-Pub 2010. PMID: 20551059.
Vagefi PA, Stangenberg L, Krings G, Forcione DG, Wargo JA. Ocular melanoma metastatic to the pancreas after a 28-year disease-free interval. Surgery 148(1):151-4, 2010. e-Pub 2010. PMID: 19744448.
Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 184(11):5988-98, 2010. e-Pub 2010. PMID: 20427771.
Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 184(11):5988-98, 2010. e-Pub 2010.
Konstantinidis IT, Deshpande V, Zheng H, Wargo JA, Fernandez-del Castillo C, Thayer SP, Androutsopoulos V, Lauwers GY, Warshaw AL, Ferrone CR. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?. J Gastrointest Surg 14(2):261-7, 2010. e-Pub 2010. PMID: 19937477.
Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernandez-Del Castillo C. Incidental pancreatic cysts: do we really know what we are watching?. Pancreatology 10(2-3):144-50, 2010. e-Pub 2010. PMID: 20484954.
Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 58(3):383-94, 2009. e-Pub 2009. PMID: 18677478.
Singh AK, Sahani DV, Blake MA, Joshi MC, Wargo JA, Fernandez-del Castillo C. Assessment of pancreatic tumor resectability with multidetector computed tomography: semiautomated console-generated images versus dedicated workstation-generated images. Acad Radiol 15(8):1058-68, 2008. e-Pub 2008. PMID: 18620126.
Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180(9):6116-31, 2008. e-Pub 2008. PMID: 18424733.
Shah ZK, Uppot RN, Wargo JA, Hahn PF, Sahani DV. Small bowel obstruction: the value of coronal reformatted images from 16-multidetector computed tomography--a clinicoradiological perspective. J Comput Assist Tomogr 32(1):23-31, 2008. e-Pub 2008. PMID: 18303284.
Peterfreund RA, Wargo JA. Errant central line placement. J Clin Anesth 19(6):479-81, 2007. e-Pub 2007. PMID: 17967683.
Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther 12(6):516-27, 2005. e-Pub 2005. PMID: 15775996.
Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27(5):354-67, 2004. e-Pub 2004. PMID: 15314544.
Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol 172(8):4762-9, 2004. e-Pub 2004. PMID: 15067052.
Huggett A, Petersen BJ, Walker R, Fisher CE, Notermans SH, Rombouts FM, Abbott P, Debackere M, Hathaway SC, Hecker EF, Knaap AG, Kuznesof PM, Meyland I, Moy G, Narbonne JF, Paakkanen J, Smith MR, Tennant D, Wagstaffe P, Wargo J, Wurtzen G. Towards internationally acceptable standards for food additives and contaminants based on the use of risk analysis. Environ Toxicol Pharmacol 5(4):227-36, 1998. e-Pub 1998. PMID: 21781869.
Murdoch DJ, Krewski D, Wargo J. Cancer risk assessment with intermittent exposure. Risk Anal 12(4):569-77, 1992. e-Pub 1992. PMID: 1480801.
Gould EJ, Wargo J. Home health nursing care plans. NLN Publ(21-2195):207-13, 1987. e-Pub 1987. PMID: 3684546.
Cobb CF, Van Thiel DH, Wargo J. Ethanol inhibition of glucose absorption in isolated, perfused small bowel of rats. Surgery 94(2):199-203, 1983. e-Pub 1983. PMID: 6410524.
Adler IL, Jones BM, Wargo JP Jr. Fate of 2-chloro-1-(3-ethoxy-4-nitrophenoxy)-4-(trifluoromethyl) benzene (oxyfluorofen) in rats. J Agric Food Chem 25(6):1339-41, 1977. e-Pub 1977. PMID: 915134.
Wargo JP, Honeycutt RC, Adler IL. Characterization of bound residues of nitrofen in cereal grains. J Agric Food Chem 23(6):1095-7, 1975. e-Pub 1975. PMID: 1194571.
Adler IL, Wargo JP Jr. Determination of residues from the herbicide 2,4-dichloro-1-(4-nitrophenoxy)-benzene in rice and wheat by electron capture gas-liquid chromatography. J Assoc Off Anal Chem 58(3):551-3, 1975. e-Pub 1975. PMID: 1141185.
Adler IL, Haines LD, Wargo JP Jr. Studies with dairy cows and laying hens fed alfalfa containing field-aged residues due to 3,5-dichloro-N-(1,1-dimethyl-2-propynyl)benzamide. J Agric Food Chem 20(6):1233-5, 1972. e-Pub 1972. PMID: 5083531.
Adler IL, Gordon CF, Haines LD, Wargo JP Jr. Determination of residues from herbicide N-(1,1-dimethylpropynyl)-3, 5-dichlorobenzamide by electron capture gas-liquid chromatography. J Assoc Off Anal Chem 55(4):802-5, 1972. e-Pub 1972. PMID: 5066464.
WARGO J. THE UDOFT FLIGHT SIMULATION SYSTEM. TECHN DOCUM REP AMRL-TDR-63-133. AMRL TR:1-280, 1963. e-Pub 1963. PMID: 14131200.
WARGO J, TEICHNER R, FERGUSON JH. Sulfamethoxypyridazine (kynex)--an evaluation in urinary tract infections. Am J Obstet Gynecol 80:490-4, 1960. e-Pub 1960. PMID: 13783165.
HOPMAN BC, WARGO JD, WERCH SC. Cytology of vernix caseosa cells. Obstet Gynecol 10(6):656-9, 1957. e-Pub 1957. PMID: 13484177.
NAHAS GG, MATHER GW, WARGO JD, ADAMS WL. Influence of acute hypoxia on sympathectomized and adrenalectomized dogs. Am J Physiol 177(1):13-5, 1954. e-Pub 1954. PMID: 13148333.
LILLEHEI CW, WARGO J, HAMMERSTROM RN. Experimental bacterial endocarditis and proliferative glomerulonephritis; description of method of production utilizing bilateral lower extremity or single aorta-vena cava arteriovenous fistulas. Dis Chest 24(4):421-44, 1953. e-Pub 1953. PMID: 13095256.
BOBB JR, WARGO JD, VISSCHER MB. The comparative susceptibility to endocarditis and glomerulonephritis in dogs with and without arteriovenous shunts. J Lancet 71(10):455-61, 1951. e-Pub 1951. PMID: 14874026.
LILLEHEI CW, SHAFFER JM, SPINK WW, BOBB JR, WARGO JD, VISSCHER MB. Role of cardiovascular stress in the pathogenesis of endocarditis and glomerulonephritis; observations including method of experimental production utilizing arteriovenous fistulas. AMA Arch Surg 63(4):421-34, 1951. e-Pub 1951. PMID: 14868196.

Invited Articles

Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer 117(1):1-7, 2017. e-Pub 2017.
Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. Cancer 123(S11):2130-2142, 2017. e-Pub 2017.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4):707-723, 2017. e-Pub 2017.
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 122(15):2299-312, 2016. e-Pub 2016.
Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep 18(7):42, 2016. e-Pub 2016.
Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31. e-Pub 2016.
Prieto PA, Reuben A, Cooper ZA, Wargo JA. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J 22(2):138-146, 2016. e-Pub 2016.
Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol 42(4):601-16, 2015. e-Pub 2015.
Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint blockade in the treatment of metastatic melanoma. Cancer Biology and Medicine 11(4):237-46, 2014. e-Pub 2014.
Reuben R, Amaria RA, Cooper ZA, Wargo JA. RAF inhibitor therapy promotes melanocytic antigen expression and enhanced anti-tumor immunity in melanoma. J Pigmentary Dis 1(5):pii: 139, 2014. e-Pub 2014.

Review Articles

Flaherty KT, Aplin AE, Davies MA, Hacohen N, Herlyn M, Hoon D, Hwu P, Lotem M, Mule J, Wargo JA, Fisher DE. Facts and Hopes: Toward the Next Quantum Leap in Melanoma. Clin Cancer Res 31(14):2882-2889, 2025. e-Pub 2025. PMID: 40407722.
Fernandez E, Wargo JA, Helmink BA. The Microbiome and Cancer: A Translational Science Review. JAMA 333(24):2188-2196, 2025. e-Pub 2025. PMID: 40354071.
Elkrief A, Routy B, Derosa L, Bolte L, Wargo JA, McQuade JL, Zitvogel L. Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship. Am Soc Clin Oncol Educ Book 45(3):e472902, 2025. e-Pub 2025. PMID: 40262063.
Stanton SE, Anderson KG, Bruno TC, Capitini CM, Disis ML, McQuade J, Radvanyi L, Vanpouille-Box C, Wargo J, Baines KJ, Hong MMY, Rajeh A, Kim RH, Awadalla P, Hughes LK, Maleki Vareki S. SITC strategic vision: prevention, premalignant immunity, host and environmental factors. J Immunother Cancer 13(3), 2025. e-Pub 2025. PMID: 40154956.
Johnston CD, Wargo JA. Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol 45(12):931-933, 2024. e-Pub 2024. PMID: 39603891.
Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AD Jr, Silk AW, Wargo JA. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer 12(6), 2024. e-Pub 2024. PMID: 38901879.
Swanton C, Bernard E, Abbosh C, Andre F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio MA, Hidalgo A, Jamal-Hanjani M, Joyce JA, Kaiser M, Lamia K, Locasale JW, Loi S, Malanchi I, Merad M, Musgrave K, Patel KJ, Quezada S, Wargo JA, Weeraratna A, White E, Winkler F, Wood JN, Vousden KH, Hanahan D. Embracing cancer complexity: Hallmarks of systemic disease. Cell 187(7):1589-1616, 2024. e-Pub 2024. PMID: 38552609.
Borthwick Bowen M, Helmink BA, Wargo JA, Yates MS. TIME for Bugs: The Immune Microenvironment and Microbes in Precancer. Cancer Prev Res (Phila) 16(9):497-505, 2023. e-Pub 2023. PMID: 37428011.
Knisely A, Seo YD, Wargo JA, Chelvanambi M. Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765735.
White MG, Wargo JA. The Microbiome in Gastrointestinal Cancers. Gastroenterol Clin North Am 51(3):667-680, 2022. e-Pub 2022. PMID: 36153116.
Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nat Med 28(4):690-703, 2022. e-Pub 2022. PMID: 35440726.
Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 22(4):195-207, 2022. e-Pub 2022. PMID: 35105962.
Erstad DJ, Witt RG, Wargo JA. Neoadjuvant therapy for melanoma: new and evolving concepts. Clin Adv Hematol Oncol 20(1):47-55, 2022. e-Pub 2022. PMID: 35060962.
Dono A, Nickles J, Rodriguez-Armendariz AG, McFarland BC, Ajami NJ, Ballester LY, Wargo JA, Esquenazi Y. Glioma and the gut-brain axis: opportunities and future perspectives. Neurooncol Adv 4(1):vdac054, 2022. e-Pub 2022. PMID: 35591978.
Witt RG, Erstad DJ, Wargo JA. Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol 14:17588359221083052, 2022. e-Pub 2022. PMID: 35251322.
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309-5337, 2021. e-Pub 2021. PMID: 34624224.
Baruch EN, Wang J, Wargo JA. Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunol Res 9(4):365-370, 2021. e-Pub 2021. PMID: 34003768.
Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science 371(6536), 2021. e-Pub 2021. PMID: 33766858.
Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, Blank CU, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ, Topalian SL, Ward AF, Hurlbert MS. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. Clin Cancer Res 27(2):394-401, 2021. e-Pub 2021. PMID: 33188142.
Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol 16(1):6-15, 2021. e-Pub 2021. PMID: 33349682.
McQuade JL, Ologun GO, Arora R, Wargo JA. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep 22(7):74, 2020. e-Pub 2020. PMID: 32577835.
Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, Whiteson KL, Gustafson HH, Slade DJ, Schmidt TM, Walther-Antonio MRS, Korem T, Webb-Robertson BM, Styczynski MP, Johnson WE, Jobin C, Ridlon JM, Koh AY, Yu M, Kelly L, Wargo JA. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer 6(3):192-204, 2020. e-Pub 2020. PMID: 32101723.
Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA. Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci 65(3):885-896, 2020. e-Pub 2020. PMID: 32067144.
Halsey T, Ologun G, Wargo J, Jenq RR. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Semin Hematol 57(1):13-18, 2020. e-Pub 2020. PMID: 32690139.
Toker J, Arora R, Wargo JA. The Microbiome in Immuno-oncology. Adv Exp Med Biol 1244:325-334, 2020. e-Pub 2020. PMID: 32301026.
McAllister F, Khan MAW, Helmink B, Wargo JA. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Cancer Cell 36(6):577-579, 2019. e-Pub 2019. PMID: 31951558.
Elinav E, Garrett WS, Trinchieri G, Wargo J. The cancer microbiome. Nat Rev Cancer 19(7):371-376, 2019. e-Pub 2019. PMID: 31186547.
Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 20(7):e378-e389, 2019. e-Pub 2019. PMID: 31267972.
Keung EZ, Wargo JA. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am 28(3):369-386, 2019. e-Pub 2019. PMID: 31079794.
Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med 25(3):377-388, 2019. e-Pub 2019. PMID: 30842679.
McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol 20(2):e77-e91, 2019. e-Pub 2019. PMID: 30712808.
Cogdill AP, Gaudreau PO, Arora R, Gopalakrishnan V, Wargo JA. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol 39(11):900-920, 2018. e-Pub 2018. PMID: 30392721.
Routy B, Gopalakrishnan V, Daillere R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol 15(6):382-396, 2018. e-Pub 2018. PMID: 29636538.
Eggermont AMM, Crittenden M, Wargo J. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book 38:197-207, 2018. e-Pub 2018. PMID: 30231333.
Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell 33(4):570-580, 2018. e-Pub 2018. PMID: 29634945.
Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol 9:946, 2018. e-Pub 2018. PMID: 29780391.
Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer 117(1):1-7, 2017. e-Pub 2017. PMID: 28524159.
Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. Cancer 123(S11):2130-2142, 2017. e-Pub 2017. PMID: 28543700.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4):707-723, 2017. e-Pub 2017. PMID: 28187290.
Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158-176, 2017. e-Pub 2017. PMID: 27859479.
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer 122(15):2299-312, 2016. e-Pub 2016. PMID: 26991400.
Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31, 2016. e-Pub 2016. PMID: 27240055.
Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep 18(7):42, 2016. e-Pub 2016. PMID: 27215436.
Prieto PA, Reuben A, Cooper ZA, Wargo JA. Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J 22(2):138-46, 2016. e-Pub 2016. PMID: 27111910.
Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizee G. Novel Treatments in Development for Melanoma. Cancer Treat Res 167:371-416, 2016. e-Pub 2016. PMID: 26601872.
Chin L, Wargo JA, Spring DJ, Kantarjian H, Futreal PA. Cancer Genomics in Clinical Context. Trends Cancer 1(1):36-43, 2015. e-Pub 2015. PMID: 28741560.
Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 42(4):601-16, 2015. e-Pub 2015. PMID: 26320064.
Amaria RN, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther 4:79-89, 2015. e-Pub 2015. PMID: 27471714.
Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 4(12):1377-86, 2014. e-Pub 2014. PMID: 25395294.
Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 11(4):237-46, 2014. e-Pub 2014. PMID: 25610709.
Nehra D, Oyarvide VM, Mino-Kenudson M, Thayer SP, Ferrone CR, Wargo JA, Muzikansky A, Finkelstein D, Warshaw AL, Castillo CF. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?. Pancreatology 12(4):358-63, 2012. e-Pub 2012. PMID: 22898638.
Wargo JA, Tanabe K. Surgical management of melanoma. Hematol Oncol Clin North Am 23(3):565-81, x, 2009. e-Pub 2009. PMID: 19464603.
Wargo JA, Fernandez-del-Castillo C, Warshaw AL. Management of pancreatic serous cystadenomas. Adv Surg 43:23-34, 2009. e-Pub 2009. PMID: 19845167.
Wargo JA, Warshaw AL. Surgical approach to pancreatic exocrine neoplasms. Minerva Chir 60(6):445-68, 2005. e-Pub 2005. PMID: 16401999.
Wargo JA, Economou JS. The status of gene therapy for surgical disease. Adv Surg 36:223-57, 2002. e-Pub 2002. PMID: 12465553.

Editorials

Holder AM, Wargo JA, Ross MI. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma. Ann Surg Oncol 30(12):6953-6957, 2023. PMID: 37597079.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res 29(1):154-164, 2023. PMID: 36166093.
Baruch EN, Gaglani T, Wargo JA. Fecal microbiota transplantation as a mean of overcoming immunotherapy-resistant cancers - hype or hope?. Ther Adv Med Oncol 13:17588359211045853, 2021. PMID: 34603515.
Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med 15(1):223, 2017. PMID: 29100546.
Andrews MC, Wargo JA. Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer 5:10, 2017. PMID: 28239464.

Abstracts

Burton EM, Glitza IC, AuninsJ, Mahoney J, Wortman J, Litcofsky K, Cook D, Jayaraman L, Ibrahim R, LaValle T, Hussein TA, Wargo JA. Stool donor qualification and collection from metastatic melanoma (MM) patients (pts) who have responded to checkpoint inhibitors (CPI) for manufacturing of fecal microbiota transplantation (FMT). 2019 ASCO Annual Meeting, Chicago, IL, 2019. e-Pub 2019.
Wargo JA. Inflammation and Microbiome. American Society of Microbiology Meeting, San Francisco, CA, 2019. e-Pub 2019.
Glitza IC, Burton EM, Gopalakrishnan V, Helmink BA, Aunins J, Mahoney J, Wortman J, Litcofsky K, Cook D, Jayaraman L, Sullivan R, Hamid O, Ibrahim R, LaValle T, Tawbi HA, Wargo JA. A Multicenter Phase (Ph) 1b Randomized, Double Blind, Placebo (PBO)- Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention (MSI) Administration in Combination with Anti-PD1 Therapy (tx) in Patients (pts) with Metastatic Melanoma (MM). ASCO 2019 Meeting, Chicago, IL, 2019. e-Pub 2019.
Wargo JA, Khan M, Gopalakrishnan V, McQuade JL, Andrews M, Spencer C, Helmink BA. Type-1 Gut Microbial Signature Characterized by Selective Enrichment of Clostridiales is Associated with Beneficial Responses to PD1-Blockade. American Society of Microbiology Meeting, San Francisco, CA, 2019. e-Pub 2019.
Gopalakrishnan V, Andrews MC, Chen WS, Spencer CN, Vence, LM, Reuben A, Khan MAW, Cooper ZA, Prieto PA, Tetzlaff MT, Lazar A, Hudgens CW, Mcquade JL, Haydu LE, Tawbi H, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Diab A, Patel SP, Glitza IC, Zhang J, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma is influenced by the gut microbiome. American Association for Cancer Research Annual Meeting 2019, Atlanta, GA, 2019. e-Pub 2019.
Wargo JA. Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors. American Association for Cancer Research 2019, Atlanta, GA, 2019. e-Pub 2019.
Helmink BA, Gopalakrishnan V, Khan WAH, P-O G, Sirmans E, Burton EM, Spencer CS, McQuade JL, Andrews MA, Cogdill A, Haydu LE, Arora R, Jensen VB, Harris AL, Duran AF, Martin L, Ajami N, Petrosino J, Mohamed JA, Patel S, Amaria RN, Patel SP, Narnellow G, Sceneay J, Wortman J, Jayaraman L, Cook D, LaVallee T, Heffernan T, Jenq R, Diab A, Wong MK, Gershenwald JE, Hwu WJ, Davies MA, Hwu P, Tawbi H, Glitza IC, Wargo JA. Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals. ASCO 2019 Meeting, Chicago, IL, 2019. e-Pub 2019.
Wargo JA, Spencer C, Haslip J. Probiotics Linked to Poorer Response to Cancer Immunotherapy in Skin Cancer Patients Study. American Association for Cancer Research 2019, Atlanta, GA, 2019. e-Pub 2019.
Spencer CN, Gopalakrishnan V, McQuade JL, Andrews, MA, Khan MAW, Helmink B, Cogdill AP, Sirmans E, Haydu E, Posada EL, Burton EM, Glitza IC, Amaria RN, Patel SP, Diab A, Wong MK, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq RR, Nelson K, Daniel CR, Cohen L, Wargo JA. The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. Parker Institute for Cancer Immunotherapy, San Francisco, CA, 2019. e-Pub 2019.
Sloane RS, Andrews M, Han G, Haydu LE, Burton E, Gernshwald JE, Wargo JA. Identification of microRNAs associated with melanoma immunity and immunotherapy outcome. American Association for Cancer Research 2019 Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Wargo JA. Biomarkers of response and toxicity to cancer therapy: The whole is greater than the sum of its parts. American Association for Cancer Research 2019, Atlanta, GA, 2019. e-Pub 2019.
Helmink BA, Reddy SM, Bailey MD, Bahrami AJ, Liang Y, Warren S, Gopalakrishnan V, Tawbi HA, Amari RN, Davies MA, Gershenwald JE, Burton EM, Basar R, Lazar AJ, Hudgens CW, Rezvani K, Allison J, Sharma P, Beechem JM, Wargo JA, Tetzlaff, MT. NanoString®GeoMx®digital spatial profiling further defines the role of B-cells in the response to immune checkpoint blockade. American Association for Cancer Research 2019 Meeting, Atlanta, GA, 2019. e-Pub 2019.
Reddy S, Helmink B, Zhang S, Blando J, Han G, Amaria R, Tawbi HA, Davies MA, Hwu P, Gershenwald JE, Burton EM, Hudgens C, Keung E, Gaudreau PO, Gopalakrishnan V, Reuben A, Miles C Andrews MC, Spencer C, Allison J, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB). Society for Immunotherapy of Cancer 2018 Meeting, Washington, DC, 2018. e-Pub 2018.
Gopalakrishnan V, Spencer CS, McQuade JL, Andrews MA, Helmink B, Cogdill AP, Khan MAW, Sirmans E, Haydu LE, Posada EL, Burton EM, Glitza IC, Amaria RN, Patel SP, Diab A, Wong MK, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo JA. Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals – implications for clinical trial design. Society for Immunotherapy of Cancer 2018 Meeting, Washington, DC, 2018. e-Pub 2018.
Gopalakrishnan V, Spencer CS, McQuade JL, Andrews MA, Helmink B, Cogdill AP, Khan MAW, Sirmans E, Haydu LE, Posada EL, Burton EM, Glitza IC, Amaria RN, Patel SP, Diab A, Wong MK, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo JA. The gut microbiome of metastatic melanoma patients initiating systemic therapy is influenced by host factors including diet, probiotic and antibiotic use. Society for Immunotherapy of Cancer 2018 Meeting, Washington, DC, 2018. e-Pub 2018.
Gopalakrishnan V, Helmink BA, Gaudreau PO, Spencer CS, Harris AL, McQuade JL, Andrews MC, Cogdill AP, Jensen VB, Duran AF, Heffernan T, Jamal MA, Claudia IC, Tawbi H, Amaria RN, Wong MKK, Arora R, Burton EM, Sirmans E, Jenq RR, Gershenwald JE, Davies MA, Wargo JA. Implications for clinical trial design based on host factors and variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals. 8th Annual Postdoctoral Science Symposium at MD Anderson Cancer Center, Houston, TX, 2018. e-Pub 2018.
Cogdill AP, Wei SC, Nezi L, Anang NAS, Gaudreau PO, Andrews MC, Spencer CN, Ajami N, Jenq RR, Gopalakrishnan V, Allison JP, Wargo JA. Compositional differences in the gut microbiome are associated with distinct tumor and systemic immune profiles in melanoma. Society for Immunotherapy of Cancer 2018 Meeting, Washington, DC, 2018. e-Pub 2018.
McQuade JL, Gopalakrishnan V, Spencer CS, Andrews MA, Helmink B, Cogdill AP, Sirmans E, Haydu LE, Posada EL, Burton EM, Glitza IC, Amaria RN, Patel SP, Diab A, Wong MK, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo JA. The gut microbiome of melanoma patients is distinct from that of healthy individuals and is impacted by probiotic and antibiotic use. Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. e-Pub 2018.
Andrews MC, Chen SY, Hudgens CW, Tetzlaff MT, Amaria RN, Arur S, Heffernan TP, Wargo JA. Sexual dimorphism in response to BRAFmut melanoma targeted therapy. Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. e-Pub 2018.
Reddy S, Helmink B, Zhang S, Blando J, Han G, Amaria R, Tawbi HA, Davies MA, Hwu P, Gershenwald JE, Burton EM, Hudgens C, Keung E, Gaudreau PO, Gopalakrishnan V, Reuben A, Miles C Andrews MC, Spencer C, Allison J, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cell signature predicts survival in melanoma and response to immune checkpoint blockade (ICB). Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. e-Pub 2018.
Cogdill AP, Wei SC, Nezi L, Anang NAS, Gaudreau PO, Andrews MC, Spencer CN, Ajami N, Jenq RR, Gopalakrishnan V, Allison JP, Wargo JA. Compositional differences in the gut microbiome are associated with distinct tumor and systemic immune profiles in melanoma. Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. e-Pub 2018.
Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Hutchinson D, Hoffman K, Prieto P, Vicente D, Tetzlaff M, Lazar A, Davies M, Gershenwald JE, Hwu P, Hwu WJ, Sharma P, Allison J, Futreal A, Cooper Z, Ajami N, Petrosino McDougal CD, Jenq R, Wargo JA. Diversity and composition of the gut microbiome are associated with differential responses to anti-PD1-therapy in melanoma patients. 8th Annual Postdoctoral Science Symposium at MD Anderson Cancer Center, Houston, TX, 2018. e-Pub 2018.
Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan TP, Amaria RN, Korkut A, Peng W, Roszik J, Lizee G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res. e-Pub 2018. PMID: 29496759.
Kim A, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, Yee C, Hwu WJ, Bernatchez C, Wargo JA, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):137, 2015. e-Pub 2015.
Chen PL, Roh W, Reuben A, Spencer CN, Jiang H, Lazar A, Davies M, Miller JP, Wani K, Hwu P, Patel S, Woodman S, Glitza I, Hwu WJ, Cooper ZA, Allison J, Sharma P, Wistuba I, Blando J, Prieto V, Tetzlaff M, Amaria R, Futreal A, Chin L, Wargo JA. Immune infiltrate in early on-treatment biopsies is highly predictive of response to immune checkpoint blockade. Society of Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
De Macedo MP, Reuben A, Qin Y, Reddy S, Spencer CN, Jiang H, Bernatchez C, Austin-Breneman JL, Gopalakrishnan V, Guindani M, Gombos D, Esmaeli B, Grimm EA, Chattopadhyay C, Oba J, Woodman S, Hwu P, Williams M, Tetzlaff M, Cooper ZA, Wargo JA, Lazar A, Patel S. Understanding the determinants of resistance to therapy in metastatic uveal melanoma. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Garman B, Krepler C, Sproesser K, Brafford P, Wilson M, Wubbernhorst B, Amaravadi R, Bennett J, Berqiri M, Davies M, Elder D, Flaherty KT, Frederick D, Gangadhar TC, Hoon D, Karakousis G, Mitra N, Petrelli N, Schuchter L, Wargo JA, Xiao M, Xu X, Herlyn M, Nathanson KL. Translating TCGA findings into reagents: massively parallel sequencing (MPS) of PDX and cell lines identifies multiple known and novel sub-sets of cutaneous melanoma. Society for Melanoma Research Congress 2015 San Francsico, CA USA, 2015. e-Pub 2015.
McQuade J, Guo C, Panka D, Reuben A, Bassett R, Joon A, Lazar A, Tetzlaff M, Simpson L, Mouton R, Glitza I, atel S, Hwu WJ, Amaria R, Diab A, Hwu P, Wargo JA, Sullivan R, Kim K, Davies M. Phase II study of dabrafenib (D) and trametinib (T) following progression on BRAF inhibitor (BRAFi): clinical and molecular predictors of response. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Kim H, Frederick D, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill LM, Samuels Y, Hayward N, Perlina A, Zhang T, Herlyn M, Brown K, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. JAK1 deregulation by the ubiquitin ligase RNF125 underlies response of melanoma cells to BRAF inhibitors and expression of PD-1 ligands. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Kim DW, Haymaker C, Perdon K, Amaria R, Mcquail N, Fa'ak F, Spencer CN, Sirmans E, Glitza I, Wargo JA, Woodman S, Patel S, Davies M, Hwu WJ, Bernatchez C, Hwu P, Diab A. Phase II trial of nab-paclitaxel (ABI) plus ipilimumab (ipi) in patients with metastatic melanoma (MM). Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Kaur A, Marchbank K, Webster M, Behera R, Dang V, Appleton J, O'Connell M, Cheng P, Valiga A, Ndoye A, Morissette R, McDonnell N, Ferrucci L, Meeth K, Bosenberg M, Flaherty KT, Wargo JA, Aird K, Xu X, Ribas A, Speicher D, Long GV, Liu Q, Schadendorf D, Weeraratna A. Aging microenvironment modulates melanoma invasion and therapy resistance. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Jiang H, Prieto P, Reuben A, Austin-Breneman JL, Spencer CN, Gershenwald J, Cormier J, Lee J, Royal R, Lucci A, Ross M, Griffin K, Amaria R, Cooper ZA, Wargo JA, Tetzlaff M. Treatment with neoadjuvant BRAF/MEK inhibitors yields high response rates in patients with resectable metastatic melanoma. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Cooper ZA, Reuben A, Prieto P, Spencer CN, Austin-Breneman JL, Jiang H, Chen PL, Haymaker C, Amaria R, Vence L, Frederick D, Sullivan R, Flaherty KT, Gershenwald J, Prieto V, Davies M, Patel S, Glitza I, Diab A, Hwu WJ, Hwu P, Tetzlaff M, Chin L, Dwyer KC, Wargo JA. Patterns of immune infiltrate differ at progression on targeted therapy versus immune checkpoint blockade for melanoma. Society for Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Austin-Breneman JL, Reuben A, Spencer CN, Roszik J, Miller JP, Kwong L, Jiang H, Roh W, Cao Y, Little LD, Amaria R, Garber HR, Gopalakrishnan V, Chen PL, Haymaker C, Forget MA, Davies M, Bernatchez C, Tetzlaff M, Woodman S, Dwyer KC, Chin L, Futreal A, Cooper ZA, Wargo JA. Immune and molecular heterogeneity in synchronous melanoma metastases. Society of Melanoma Research Congress 2015 San Francisco, CA USA, 2015. e-Pub 2015.
Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen PL, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget MA, Gopalakrishnan V, Amaria R, Davies M, Bernatchez C, Roger E, Cuentas P, Rodriguez J, Tetzlaff M, Woodman S, Dwyer K, Sharma P, Allison J, Chin L, Futreal A, Cooper Z, Wargo JA. Molecular and immune heterogeneity in synchronous melanoma metastases. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):262, 2015. e-Pub 2015.
Reuben A, Cooper ZA, Amaria RN, Forget MA, Haymaker C, Bernatchez C, Chen PL, Tetzlaff MT, Chin L, Dwyer KC, Wargo JA. Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma. Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):200, 2014. e-Pub 2014.
Amaria RN, Cooper ZA, Chen P, Boland, G, Davies MA, Ross MI, Tetzlaff MT, Wargo JA. Treatment with neoadjuvant BRAF/MEK inhibition results in a pathologic complete response in a patient with locally advanced melanoma. Society for Melanoma Research Congress, Zurich, Switzerland, 2014. e-Pub 2014.
Sabbatino F, Wang Y, Wang X, Flaherty KT, Pepin D, Scognamiglio G, Yu L, Cooper ZA, Pepe S, Kirkwood JM, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Cooper ZA, Reuben A, Amaria RN, Forget MA, Haymaker C, Bernatchez C, Chen P, Tetzlaff MT, Chin L, Dwyer KC, Wargo JA. Immune and T cell receptor heterogeneity between multiple tumors within individual melanoma patients. Tumor Immunology and Immunotherapy: A New Chapter, Orlando, Florida, USA, 2014. e-Pub 2014.
Cooper ZA, Amaria RN, Reuben A, Chen P, Haymaker C, Tetzlaff MT, Davies MA, Flaherty KT, Chin L, Dwyer KC, Wargo JA. Differential patterns of leukocyte infiltrate at progression on targeted therapy versus immunotherapy for melanoma. Society for Melanoma Research Congress, Zurich, Switzerland, 2014. e-Pub 2014.
Vashisht Gopal YN, Rizos H, Chen G, Deng W, Federick DT, Cooper ZA, Scolyer RA, Pupo G, Smith PD, Wargo JA, Long GV, Davies MA. mTOR kinase inhibition induces nuclear exclusion of MITF and overcomes oxidative phosphorylation-mediated resistance to MAPK pathway inhibitors. Society for Melanoma Research Congress, Zurich, Switzerland, 2014. e-Pub 2014.
Krepler C, Sproesser K, Brafford P, Xiao M, Beqiri M, Xu W, Nathanson K, Wargo JA, Flaherty K, Morton DL, Hoon DS, Ryan R, Guarino M, Petrelli NJ, Elder D, Xu X, Karakousis G, Schuchter L, Herlyn M. Patient derived xenograft (PDX) of human melanoma to predict clinical responses. Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Reuben A, Cooper ZA, Amaria RN, Forget MA, Haymaker C, Bernatchez C, Chen P, Tetzlaff MT, Chin L, Dwyer KC, Wargo JA. Immune heterogeneity is evident between multiple tumors within individual melanoma patients on targeted therapy and immunotherapy. Society of Immunotherapy of Cancer 29th Annual Meeting, Washington D.C., USA, 2014. e-Pub 2014.
Goff SL, Ligorio M, Wargo JA, Cooper Z, Frederick DT, Sabatino F, Deshpande V, Ferrone CR. Improving the detection of mitoses in pancreatic neuroendocrine tumors using phosphohistone H3. Digestive Disease Week, Orlando, FL, 2013. e-Pub 2013.
Miller JP, Frederick, D, Shah P, Wargo JA, Cooper ZA, Lawrence DP, Hodi FS, Hwu P, freeman G, Sharpe A, Flaherty KT, Chin L. Identification of early-treatment prognostic indicators for responsive therapy in mutant BRAF melanoma. NCI–TMEN January 2013 Steering Committee Meeting, New York, NY, 2013. e-Pub 2013.
Wagle N, Van Allen EM, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, Flaherty K, Wargo JA, Garraway LA. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. ASCO, Chicago, IL, 2013. e-Pub 2013.
Smith MP, Brunton H, Rana S, Ferguson J, Arozarena I, Frederick DT, Cooper ZA, Flaherty KT, Marais R, Wargo JA, Wellbrock C. MITF and the response to MAP-kinase pathway targeted therapy in melanoma. Society for Melanoma Research Congress, Philadelphia, PA, 2013. e-Pub 2013.
Frederick DT, Ahmed Z, Cooper ZA, Straussman R, Shee K, Ferrone C, Ferrone S, Sharpe AH, Flaherty KT, Fisher DE, Wargo JA. Stromal fibroblasts contribute to the up-regulation of PD-L1 in melanoma after BRAF inhibition. Society for Melanoma Research Congress, Philadelphia, PA, 2013. e-Pub 2013.
Cooper ZA, Juneja V, Sage PT, Mitra D, Lo JA, Frederick DT, Piris A, Ferrone C, Lawrence DP, Sullivan RJ, Freeman G, Flaherty KT, Sharpe AH, Fisher DE, Wargo JA. Response to BRAF inhibition in melanoma is enhanced by the addition of immune checkpoint blockade. Society for Melanoma Research Congress, Philadelphia, PA, 2013. e-Pub 2013.
Fiedler A, Cooper, ZA, Frederick DT, Cogdill A, Rosenberg L, Ferrone, CR, Flaherty K, Lawrence DP, Wargo JA. BRAF Inhibition in Melanoma Results in a More Favorable Tumor Microenvironment. 65th Annual Symposium for the Society of Surgical Oncology, Orlando, FL, 2012. e-Pub 2012.
Cogdill AP, Boni A, Dang P, Udayakumar D, Njauw CJ, Sloss CM, Ferrone CR, Flaherty KT, Lawrence, DP, Fisher DE, Tsao H, Wargo JA. Inhibition of BRAF-V600E increases melanocyte antigen expression and antigen-specific recognition in melanoma without altering T cell function. Oral presentation at the Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
Cogdill AP, Boni A, Dang P, Ferrone CR, Thayer SP, Alsina J, Sloss CM, Fernandez-del-Castillo C, Warshaw AL, Wargo JA. Treatment with chromatin remodeling agents increases MAGE-A3 expression in pancreatic cancer and enhances antigen-specific recognition by T lymphocytes. Poster presentation at the Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
Wargo JA, Chinnasamy N, Hong J, Garber H, Riley J, Parkhurst M, Rosenberg SA, Morgan RA. Generation of T cell receptors targeting the MAGE-A3 cancer testis antigen for adoptive immunotherapy of cancer. Presented at the Cancer Immunology Immunotherapy Meeting at the National Cancer Institute, National Institutes of Health Bethesda, MD, 2008. e-Pub 2008.
Wargo JA, Ribas A, Glaspy JA, McBride WH, Butterfield LH, Economou JS. Genetic immunotherapy using melanoma-antigen-engineered dendritic cells generates potent immunity in MHC class I knockout mice. Presented at the annual meeting of the Society of Surgical Oncology, 2003. e-Pub 2003.
Wargo JA, Leong M, Murasko DM, Kahng KU. Interferon-gamma (IFN-y) stimulates release of nitric oxide (NO) in macrophages primed by bile duct ligation. Presented at the annual meeting of the Association for Academic Surgery, 1998. e-Pub 1998.
Liu T, Wargo JA, Leong M, Murasko DM, Kahng KU. Nitric oxide (NO) production by splenocytes is increased after bile duct ligation (BDL) in the rat. Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, 1997. e-Pub 1997.
Wargo JA, Turchi R, McGovern P, Brodkey A. Wellness in aging: health promotion with older adults. Presented at the Philadelphia Community Health Internship Symposium, 1995. e-Pub 1995.

Book Chapters

White, MG, Wargo, J, McQuade, JL. Microbiome and Cancer Metastasis, 767-773, 2022.
Toker J, Arora R, Wargo JA. The Microbiome in Immuno-oncology. In: Immunotherapy. Advances in Experimental Medicine and Biology. Springer Nature, 325-344, 2020.
Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel Treatments in Development for Melanoma. In: Cancer Treat Res. Springer, 371-416, 2016.
Cooper Z, Wargo JA. BRAF targets in melanoma. In: Biological Mechanisms, Resistance, and Drug Discovery Series. Cancer Drug Discovery and Development. Humana Press, 221, 2015.
Wargo JA. Abdominal trauma 3. Hepatic and biliary tract injuries (chapter 27). In: The Trauma Handbook of the Massachusetts General Hospital, 2001.
Wargo JA, Kahng KU. Pathophysiology and treatment of gallstone disease in the elderly (chapter 53). In: Principles and Practice of Geriatric Surgery, 1998.

Letters to the Editor

Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25: 3469-3470, 2019.
Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol 137: 1792-1795, 2017.
Fernandez-del Castillo CF, Thayer SP, Ferrone CR, Wargo J. Surgery for small and asymptomatic branch-duct IPMNs. Ann Surg 259: e47, 2014.

Patents

Generation of HLA-A2 T Cell Receptor Targeting the MAGE-A3 Antigen. Patent Number: 0000.
Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR Targeting The HLA-A*0201-restricted Epitope Of MAGE-A3 Recognizes Multiple Epitopes Of The MAGE-A Antigen Superfamily In Severval Types Of Cancer.

Less

CV information above last modified March 27, 2026

Jennifer Wargo, M.D., M.M.Sc.

About Dr. Jennifer Wargo

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patents

Patient Reviews

Request an Appointment

Related Links

Wargo Laboratory

Surgical Oncology department

Genomic Medicine department

Surgery division

Cancer Medicine division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson